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Cardiovascular disease is the main cause of mortality and morbidity in 
developed countries worldwide. Despite advances in clinical medicine, 
cardiovascular disease is responsible for 38.5 percent of all deaths in the 
United States, or one death every 34 seconds. Furthermore, cardiovascular 
disease has claimed the lives of more females than males since 1984. About 
65 million Americans suffer from one or more forms of cardiovascular 
disease, 13.2 million of which have coronary artery disease and 5 million 
suffer from congestive heart failure. In the Netherlands, approximately 
675,000 patients suffer from coronary artery disease (CAD). In 2004 90,000 
patients were admitted for coronary heart disease. Furthermore, 179,000 
patients suffer from heart failure and 27,100 patients suffer from stroke 
each year5. In addition, obesity, diabetes are commonplace among western 
countries, ensuring an increase in cases and extent of cardiovascular 
disease. The United States alone have spent over 360 billion USD treating 
cardiovascular disease6. In the Netherlands, CAD is placed among the top 5 
of most expensive illnesses5. Diagnosis of cardiovascular disease can be 
done through a large array of technologies such as computer tomography 
(CT), magnetic resonance imaging (MRI), angiography, echography and 
electrocardiography (ECG). These technologies allow us to visualize the 
anatomy of the problem to great detail. They offer insight into the extent of 
damage that has been sustained, for instance due to atherosclerosis or 
infarction. However, these technologies only provide limited biological 
information about the patient’s disease, and so can only inform us about 
the late, anatomical changes that have taken place in the patient. 
 
Recent studies have shown that myocardial infarction does not occur often 
due to progressive luminal stenosis. Instead, underlying vascular pathology 
such as inflammation, macrophage activation and apoptosis lead to forma
tion of unstable plaques with a large lipid core, thin fibrous cap and exten
sive cytokine activation. Such unstable plaques are prone to rupture and 
formation of an occlusive thrombus. Unfortunately, we are unable to 
identify patients with impeding acute myocardial infarction (AMI) or stroke. 
Knowledge of molecular changes preceding such events may present 
opportunity for early detection and intervention in these patients. 
 
A similar diagnostic problem occurs in diagnosing and treating patients at 
risk for developing congestive heart failure (CHF). As most patients survive 
their first acute cardiovascular event, the incidence of patients with dam
aged hearts increases. Current imaging technology provides excellent 
insight into ventricular systolic and diastolic function. However, we lack the 
ability to discriminate patients that will develop CHF from patients that will 
recover from the primary event. Animal testing has led to profound insight 
into neurohumoral mechanisms underlying CHF, and augmenting neuro
humoral activation improves complaints and prognosis of patients. Using 
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animal models, understanding of effects of multiple mediators on cardiac 
function has improved greatly in recent years. Despite obvious gain in 
understanding and treating CHF, clinicians are unable to predict patients at 
risk for adverse left ventricular remodeling. Again, knowledge of the under
lying biological processes could enable early detection and prevention. 
 
Unknown intracardiac masses present a diagnostic problem. Intracardiac 
masses are much more infrequent than CAD but new imaging techniques 
are also needed here. In addition, proof of concept of new imaging tech
niques may be obtained in these patients. Classical imaging modalities can 
visualize size, shape, location and haemodynamic consequences in great 
detail, but are unable to inform us about the nature of the mass7. Intracar
diac masses comprise tumors, vegetations and thrombi. Subsets of these 
masses are associated with unfavorable outcome, such as malignant tumor, 
infective endocarditis and fresh thrombus. Obtaining biological informa
tion in addition to anatomical diagnosis may therefore have clinical implica
tions. 
MOLECULAR IMAGING IN GENERAL 
Molecular imaging is a swiftly developing technique that aims to visualize 
the biology and physiology of disease in the organisms in a repetitive and 
noninvasive way8. The limited spatial resolution of conventional imaging 
techniques such as CT of MRI does not allow visualization of anatomic 
consequences of disease below a size of 0.5 to 1 cm. This limitation of 
spatial resolution precludes detection of early stages of disease. In addi
tion, once an anatomical consequence of a disease has been diagnosed, 
conventional imaging does not provide us with biological or molecular 
information about the anatomical abnormality9. 
 
The challenges that face successful molecular imaging are similar to drug 
targeting. One needs to find a target molecule that accumulates in the 
tissue of interest in a high enough dose to be visualized but without losing 
target properties after labeling with a marker, such as fluorescent probes, 
MRI or CT contrast, or radioactive agents. Finding the correct molecule for 
imaging will be driven by understanding of the biology of the underlying 
disease. By imaging biological changes preceding disease (see figure 1), 
clinicians may arrive earlier at the correct diagnosis. This opens the way for 
early, aggressive, targeted treatment. Furthermore, it can provide informa
tion on lesions not suitable for biopsy taking. Thirdly, it may serve as a 
surrogate endpoint when evaluating success of novel drugs. Finally, mo
lecular imaging could become a valuable tool for obtaining proof of con
cept for a given labeled target molecule in terms of targeting properties 
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and efficacy. In conclusion, one could state that molecular imaging could 
not only serve as a novel tool for the early detection of cardiovascular 
disease, but also may provide the key to new drug targeting options. 
 
 
 
Figure 1: 
 Molecular imaging versus anatomical imaging. Molecular imaging detects changes on a molecu
lar level, preceding the changes in anatomy. Potentially, detecting disease in an early stage may 
aid clinicians and patients, enabling early treatment. In addition, scans can be easily repeated 
studying effect of treatment. Furthermore, information on lesions not suitable for biopsy taking 
can be acquired. For cull color image see page 91 
 
 
As we will demonstrate below, phosphatidylserine (PS) expression is an 
attractive target for imaging biological processes underlying cardiovascular 
disease. The most well studied form of PS exposure linked to cardiovascu
lar disease is PS exposure associated with apoptosis, or programmed cell 
death. However, PS exposure is not solely associated with apoptosis, as it 
can be seen in activated macrophages and lymphocytes, as well as in 
activated platelets. 
PS expression can therefore be found in unstable plaques due to local 
inflammation and apoptosis. In addition, numerous studies have indicated 
that apoptosis is an important underlying mechanism in the development 
of CHF. We therefore hypothesize that imaging of PS exposure is helpful in 
gaining insight into molecular events preceding clinical cardiovascular 
disease, and could therefore have additional diagnostic value. 
NORMAL PHOSPHATIDYLSERINE DISTRIBUTION IN CELL MEMBRANES 
The phospholipid bilayer of the plasma membrane can be seen as a pair of 
parallel sheets providing a matrix for supporting membrane proteins. 
However, an increasing body of evidence supports an important role for 
the composition of this bilayer. The bilayer surrounding cells is asymmet
ric10, and cholinecontaining lipids, phosphatidylcholine (PC) and sphin
gomyelin (SM) are primarily found on the outer membrane of normal cells. 
The cytosolic, inner membrane of cells is mostly made up of amine contain
Predisease state Beginning of disease Anatomical changes Physiological changes 
Molecular imaging Conventional imaging
 Early detection
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ing phospholipids, such as phosphatidylethanolamine (PE), phosphatidyl
serine (PS). Some minor phospholipids like phosphatic acid (PA), phos
phatidylinositol (PI) and phosphatidylinosotolmonophosphate (PIP) are 
also preferentially located in the cytosolic side of the cell membrane. The 
synthesis of these lipids inherently causes asymmetry, as the enzymes 
responsible for synthesis of lipids are typically located in the cytosol of 
cells. The major glycophospholipids, PS, PC, PE, and PI are generated in the 
endoplasmatic reticulum (ER)11, and are transported by a lipid transporter 
across the ER membrane12, 13. This should cause even distribution of lipids 
across the ER membrane. However, in normal cells the plasma membrane is 
asymmetric. Consequently there should be a process controlling distribu
tion of phospholipids across the plasma membrane, producing asymmetry. 
Causing asymmetry is an active process, requiring input of energy for 
development of this asymmetry. Both outward and inward lipid transport
ers are ATP dependent. 
The makeup of the plasma membrane prevents spontaneous redistribution 
(also termend “flipflop”) of phospholipids, and half time for such a flip
flop is several hours to days and depends on the nature of the lipid and the 
membrane14. Therefore spontaneous flipflop has very limited impact. The 
most important contributors to membrane asymmetry are proteins that 
catalyze the movement of lipids across the membrane. Inward transporters 
have been termed flippases (or translocases), and outward transporters 
floppases, of which several have been characterized. In addition, there is a 
category of aspecific, bidirectional lipid transporters, the scramblases. 
Activation of scramblases is not ATP dependent, but is initiated by rising 
Ca2+ concentration inside a cell. Flippase, also termed Mg2+ ATPase, is 
highly selective for PS15. It is ubiquitously distributed in erythrocytres16, but 
is has also been observed in platelets17, lymphocytes18, aortic endothelial 
cells19, fibroblasts20 and hepatocytes21. Activity is present at both the basal 
and the apical side of epithelial cells22. It seems likely that this transporter is 
essential for any membrane in which PS should only be present on the 
cytosolic side. The identity of this flippase remains elusive, although some 
candidates have been identified23. Floppases have been identified for 
cholesterol24, PC and short chain phospholipids25. The only floppase that 
has been described for PS is ABC transporter ABCA1 (ABC1), which is 
responsible for PS mediated engulfment by macrophages in c. elengans 26. 
It is unclear how this molecule is activated, but it is not involved in mainte
nance of membrane asymmetry. Like the flippases, floppases are ATP 
dependent. In contrast to these molecules, scramblases are aspecific in 
their substrate, and serve to abolish membrane asymmetry. 
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PS EXPOSURE IN APOPTOSIS 
The most well described cause of PS exposure on the outer membrane is 
that linked to apoptosis27. First described by Fadok et al, PS exposure 
during apoptosis has also been described in chick and Drosophila28, indi
cating that lipid asymmetry is a feature of cells of vertebrate and inverte
brate animals. The common ancestor of both lived somewhere in the 
Precambrian, making this process about 600 million years old29. During 
programmed cell death the translocases are blocked, probably due to 
increased concentration of Ca2+ and decreased levels of ATP. It has been 
proposed that floppase and scramblase are activated as a consequence of 
caspase 3 mediated cleavage of protein kinase Cδ30. However, caspase 
inhibition does not prevent PS exposure in in vitro models of apoptotis30, 31 
and caspase independent apoptosis is associated with PS exposure31, 
pointing to alternate mechanisms of scramblase activation. Some authors 
have suggested a role for APAF in activation of scramblases29, 32. 
NONAPOPTOTIC PS EXPOSURE 
Besides being a marker for apoptosis, rapid PS exposure is seen in platelets 
stimulated by thrombin and collagen, due to scramblase activation and 
flippase inhibition33,34. Exposed PS is essential for assembly of active 
prothrombinase35, and plays a role in activation of prothrombin36. Detec
tion of PS exposure has been used to detect fresh cloth in porcine left atrial 
thrombus37. Moreover, PS exposure has been observed in cellcell connec
tions38. Finally, Callahan et al. describe that macrophages express PS on 
their surface when activated. Molecules that bind to PS can inhibit engulf
ment by macrophages, but more interestingly, these authors find that 
Annexin A5 addition to activated macrophages also inhibits engulfment of 
apoptotic cells or PS coated vesicles by macrophages39. 
CONSEQUENCE OF PS EXPOSURE 
PS exposure is not the only, but by far the best characterized “eat me” 
signal for cells undergoing programmed cell death. Watersoluble PS can 
inhibit engulfment of apoptosis, pointing to the fact that PS exposure is not 
only a marker for apoptosis, but it also plays an important role in removal 
of apoptotic cells27. Fadok and coworkers have identified a protein that 
specifically binds PS and is required for phagocytosis40. In addition, scaven
ger receptors such as CD3641 CD68 and CD9142 recognize externalized PS43. 
Recently, it has been shown that PS exposure alone is not enough for 
engulfment by macrophages. Bridging molecules like milk fat globuline E8 
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(MFGE8)44 are necessary for macrophages to recognize and confirm PS 
exposure, so it can engulf apoptotic cells. Indeed, mice lacking the MFGE8 
gene develop autoimmune disease, a consequence of deficient clearance 
of apoptotic cells45. Such a model has been termed “tether and tickle”, in 
the sense that PS expressing cells are recognized by macrophages in 
absence of MFGE8, but are not engulfed. Only when MFGE8 is present, 
cytoskeletal rearrangement of the macrophage is achieved and the apop
totic cell can be engulfed46. PS expression serves as a powerful signal for 
macrophages to remove apoptotic cells. 
APOPTOSIS IN GENERAL 
Apoptosis, or programmed cell death is the process multi cellular organ
isms use to maintain tissue homeostasis. In addition, programmed cell 
death plays an important role in embryologic development. More impor
tantly, imbalance of apoptosis and cell division can lead to disease (Figure 
2). 
 
 
Figure 2: 
Balance of cell division and cell loss. In general it is believed that apoptosis is a mechanism used 
by organisms to maintain stable cell numbers. In the middle panel the rate of cell proliferation is 
equal to the rate of cell death, providing tissue homeostasis. Disturbance of this delicate balance 
often leads to diseases of pathological cell accumulation such as seen in cancer (upper panel). 
The lower panel shows diseases involving pathological cell loss such as neurodegenerative 
diseases of myocardial infarction. 
 
 
Targeted deletion of cells shapes organs, cuts out fingers and shapes the 
heart and thus sculpts the embryo. Both the immune system and the 
nervous system are shaped through apoptosis: cells that do not form 
integral connections with other cells are pushed towards cell death. In 
adult man, about 10 billion cells die daily just to counter amount of cells 
gained by multiplication, or mitosis. As such, programmed cell death is an 
integral part of development and life of any organism. Interestingly, the 
Rate of cell proliferation Rate of cell death
Homeostasis
Cell loss
Cell accumulation
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process of apoptosis is conserved from worm to man, allowing rapid 
translation of insights gained in animal models into clinical practice. The 
first description of apoptosis was done by Walther Flemming, who called it 
“chromatolysis” in 1885 describing nonnecrotic ovarian cells wherein the 
nuclei were breaking up. Months later Franz Nissen reported similar cells 
in lactating mammary glands. In 1910 the process was again described by a 
german anatomist, Ludwig Graper, and in 1967 Frans Wackers used the 
term “bionecrosis” to describe similar cells in mammary glands47. But major 
interest in the process only came about after it’s description by Wyllie and 
Kerr48, who introduced the term “apoptosis”. To date approximately 85,000 
publications deal with the process of apoptosis (source: national library of 
science). Consequently, most genes and proteins regulating apoptosis have 
been identified in the last 20 years. Apoptosis concerns so many parts of 
life that it has to be tightly regulated. A central role is played by enzymes 
termed the caspases (cystein aspartate specific proteases), which cause 
many of the morphological features associated with programmed cell death 
such as chromatin condensation, dissolution of the nuclear membrane, 
nuclear shrinkage and formation of apoptotic bodies. These apoptotic 
bodies are then cleared by adjacent cells and professional phagocytes4850. 
In addition, activation of caspase 3 causes one of the final steps in pro
grammed cell death, that of fragmentation of cellular DNA, through activat
ing a specific endonuclease. Classically, two pathways are defined which 
can lead to activation of the caspases, the intrinsic and extrinsic pathway. 
Both pathways react to different stimuli, which can cause the cell to initiate 
its cell death program. The intrinsic pathway is activated when external 
signals, such as binding of Fas ligand or Tumor Necrosis Factor (TNF) to its 
receptor. These receptors are also termed death receptors. The binding of 
either Fas ligand or TNF to death receptors then causes the activation of 
caspase 8, which in its turn activates a cascade of caspases. This finally leads 
to the demise of the cell and clearance of the cell remnants by macro
phages. The intrinsic pathway is activated through direct damage to the 
cell, such as radiation, serum starvation or reactive oxygen species. This in 
term leads to release of different factors from the mitochondrion, such as 
Cytochrome C, apaf1 and apoptosis inducing factor (AIF). Cytochrome C 
and apaf1 react with caspase 9 to form the apoptosome, which trigger 
further downstream apoptotic events. Both pathways converge at the 
activation of caspase 3. However, as research progresses, evidence of cross 
talk between these pathways and caspaseindependent cell death emerges, 
as more regulatory mechanisms are discovered51. Also, the classical division 
between apoptosis and necrosis has been abandoned. Rather, a model has 
been suggested with a gliding scale between classic, caspase mediated 
apoptosis, and accidental necrosis or cell lysis. The intermediate steps are 
apoptosis like programmed cell death, the “caspase independent cell 
death” and necrosislike programmed cell death, which seems to be mostly 
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mitochondrially mediated52. Except for accidental necrosis and cell lysis, all 
these forms of cell death can be influenced by administration of cell death 
inhibitors or promoters, and thus they are modifiable processes. As already 
stated, apoptosis plays an important part in life and development. Conse
quently, deregulation of programmed cell death can cause severe dysfunc
tion of the organism. In embryological development, not deleting un
wanted cells may lead to congenital malformations. In addition, apoptosis 
is important in many other diseases. A relative low amount of cell death 
compared to the mount of cell division may lead to diseases of cell accu
mulation as is observed in tumor development or autoimmune disease. In 
contrast, a relatively high amount of cell death compared to the amount of 
cell division can lead to diseases of cell loss. This type of disease is seen in 
myocardial or cerebral infarction, heart failure, myocarditis and transplant 
rejection. 
APOPTOSIS IN CARDIOVASCULAR DISEASE 
Organs that have limited or no regenerative capacities such as the heart 
and the brains may permanently suffer from loss of function due to excess 
apoptosis. In addition, intervention in the apoptotic program can decrease 
the amount of tissue loss, and preserve organ function. Myocardial apop
tosis has been associated with end stage congestive heart failure53,54, 
arrythmogenic right ventricular dysplasia55 and myocardial infarction53,56. In 
addition, cardiomyocyte apoptosis has been detected in animal models of 
ischaemia/ reperfusion57 and heart failure58,59. Cardiac myocytes have a high 
energy consumption and 30% of the volume of a cardiomyocyte is taken up 
by mitochondria. Upon ischaemia and reperfusion, mitochondria release 
proapoptotic factors such as Cytochrome C60 and reactive oxygen species 
(ROS)61, which may in turn activate downstream caspases. In addition 
proteolitically cleaved caspases 2, 3 and 7 have also been detected in 
ischaemia/ reperfusion models, suggesting a role for receptormediated 
cell death62. Thirdly, calcium overload plays an important role in cardio
myocyte apoptosis following ischaemia/ reperfusion. It has been shown 
that calcium influx inhibitors can reduce the amount of damage following 
ischaemia/ reperfusion63. Calcium overload can lead to the permeability 
transition pore (PTP), which causes release of Cytochrome C and activation 
of downstream caspases, activation of endonucleases and proteases such 
as calpain. Calpain in turn may activate proapoptotic factors such as Bid. 
All these mechanisms may provide possible targets for prevention of loss of 
contractile mass. Cardiomyocyte apoptosis usually occurs within the first 2
4 hours after the acute insult, and is subsequently followed by myocyte 
necrosis64,65. Heart failure can be caused by subsequent inadequate remod
eling, or may occur due to genetic defects, neurohumoral stress or pres
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sure overload. The amount of apoptosis is much less as compared to acute 
ischaemic events. However, one could hypothesize that continuous low
grade apoptosis can produce similar or even more extensive damage than 
acute ischaemic events. Data concerning timing and duration of apoptosis 
in heartfailure are lacking. However, several authors have shown activation 
of parts of the cell death program in animal models of heart failure58,59 and 
human biopsy samples53 and explanted hearts54. Indeed, tissue sections of 
explanted hearts from patients with end stage heart failure shows presence 
of apoptosis54 in cardiomyocytes. It has been shown in animal models of 
heart failure that intervention in apoptotic signaling can reverse cardiac 
remodeling and increase survival66. Regulating cell death could therefore 
be an important therapeutic target in disease. When novel treatment 
strategies are tested, cell death needs to be diagnosed, quantified and 
continuously monitored. 
DETECTION OF APOPTOSIS 
Apoptosis was originally identified based on morphological features such 
as chromatin condensation, dissolution of the nuclear membrane, nuclear 
shrinkage and formation of apoptotic bodies, which are then cleared by 
adjacent cells and professional phagocytes4850. DNA fragmentation, the 
hallmark of apoptosis, is identified by in situ endlabeling techniques of 
DNA fragments in the nuclei. These fragmented pieces of DNA can be 
detected by several techniques. The best known of these involves staining 
of tissue sections by the terminal deoxynucleotidyl transferase (TdT)
mediated dUTP nick endlabeling (TUNEL), in which the free 3’ –OH termini 
that occur during DNA fragmentation are labeled and detected67. Addition
ally, antibodies against single stranded DNA can be used for the detection 
of fragmented DNA. These techniques are not specific for apoptotic cell 
death, since they also detect DNA cleavage due to environmental DNA 
damage or DNA repair68. DNA fragmentation occurs secondary to the 
activation of highly specific terminal proteolytic enzymes called caspases. 
Caspases (cysteïne aspartatespecific proteases) once activated, leads to 
cleavage of cytoplasmic proteins and activation of DNAses. Since normal 
cells contain DNA fragmentation factors in their inactive form, the cleavage 
process can proceed quickly once the caspases are activated. The inhibitor 
of caspase activated deoxyribonuclease (CAD), termed ICAD, is cleaved 
during programmed cell death by caspase 3, resulting in release of CAD69. 
Detection of activated caspase 3 or caspase cleavage products can be 
performed on tissue sections as well, and thereby provide clues for detec
tion of apoptosis in addition to the morphological features and staining 
methods. Activated caspases can also be characterized and quantified by a 
variety of other techniques, including immunoblotting, cleavage of syn
CHAPTER 1 20 
thetic substrates, affinity labeling and confocal microscopy70. Earlier media
tors of apoptosis have also been characterized to address the upstream 
cascade of apoptosis. Such mediators include demonstration of pro sur
vival signals (such as IAPs XIAPs and Bclxl) and signals that drive the cell 
toward cell death such as ligation of proapoptotic death receptors and 
release of cytochrome C from mitochondria. 
 
These techniques all require samples of the target tissue. In addition, cells 
that are stressed may undergo programmed cell death, or as current evi
dence suggests, the cell death program may be interrupted, or reversed, 
before the cell dies. As a result, monitoring tissues for cell death should be 
a dynamic process, where repetitive measurements can be made in the 
same tissue. Even though immunohistochemical and/or blotting tech
niques offer high spatial resolution of the cells, the techniques do not allow 
the same cells to be followed through the cell death process. In addition, 
the tissue that is sampled is often a small fraction of the total tissue in
volved in the process, making it likely that the sample may not represent 
the true state of the tissue. This can lead to erroneous conclusions or even 
a false diagnosis. Development of a technology that allows noninvasive 
monitoring of apoptosis in vivo could therefore be of significant benefit. 
Ideally, invivo monitoring of programmed cell death should be non
invasive, suitable for repeated measurements in the same organism, safe 
and rapid8. Molecular imaging is able to combine insights in molecular 
biology with state of the art imaging technology. 
EMPLOYING LABELED ANNEXIN A5 FOR MOLECULAR IMAGING OF CELL 
DEATH 
As mentioned previously, during the process of apoptosis the normally 
asymmetric distribution of phospholipids in the cell membrane lipid bilayer 
is lost and leads to preferential expression of phosphatedyl serine (PS) on 
the outer cell membrane. PS is an avid target for a physiologic protein, 
Annexin A5. This protein can be labeled with iron oxide particles for MR 
imaging, fluorescent probes for optical imaging or radiotracers for nuclear 
imaging. The labeled Annexin A5 may traverse from the blood compart
ment it traverses through the endothelial barrier to enter the extracellular 
space over several hours. Once in the extracellular space, annexin binds to 
exteriorized PS; and may remain at the site of interaction for a sufficient 
time to permit imaging8. In addition to Annexin A5, externalized phos
phatidyl serine can be a target for other molecules. Synaptotagmin I, for 
example, has a C2 domain that binds to anionic phospholipids exposed on 
the outer membrane of cells. It has been shown that this molecule can be 
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labeled with super paramagnetic ion oxide nanoparticles (SPIOs)71 for use 
as an MRI probe. 
 
Annexin A5 binds to phospholipids in a Ca2+ dependent manner. Some 
authors propose a model in which Ca2+ causes a change in conformation of 
the binding site of Annexin A5, which can then bind to the (exposed) 
phosphatidyl serine. In 1995 this mechanism was used to develop an assay 
based on the binding of Annexin A5 to apoptotic cells72. The affinity assay 
of Martin et al and van Engelshoven et al73, 74 showed that Annexin A5 could 
be used to detect programmed cell death in vitro. In this assay, Jurkat cells, 
an immortalized cell line, were stimulated with a potent trigger for apop
tosis, Fas ligand. It was then shown that fluorescently labeled Annexin A5 
bound to these cells in all phases of the cell death program (Figure 3). 
 
 
 
Figure 3: 
 Annexin A5 binds to cells in all stages of the cell death program. Here, Jurkat cells are stimulated 
by Fas ligand. In figure 3A, the early phase of apoptosis is seen. Already we can observe binding 
of fluorescent labeled Annexin A5 to the cell membrane. Figure 3B depicts a later stage, in which 
we see formation of blebs and Annexin A5 binding. Figure 3C is the final stage of apoptosis, the 
cell remnants. These also bind labeled Annexin A5. For cull color image see page 91. 
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This concept also works in the complex environment of the living organ
ism, as several different lines of experiments in our group have shown. 
Studies on embryonic mice models show detection of developmental 
apoptosis. Appearance of apoptosis during formation of the digits takes 
place at stage E13 in the chick embryo. Biotin labeled Annexin A5 was 
administered prior to sacrifice of the organism. Binding of the labeled 
Annexin A5 was seen in the interdigital webs38, as shown in figure 4, 
thereby proving the concept that Annexin A5 has a sufficiently long circu
lating can be used for the detection of apoptosis in the complex environ
ment of a living organism. 
 
 
 
Figure 4: 
Paw of a chick embryo 
at day 13. Binding of 
labeled Annexin A5 
(note brown staining) 
can de observed in 
interdigit spaces. For 
full color image see 
page 92. 
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In addition, prior studies have shown the use of this assay for detection of 
apoptosis in pathological situations. Mimicking the situation of a myocar
dial infarction, a mouse model of ischaemia and reperfusion was used. The 
left anterior descending artery of the heart of a mouse was ligated. Prior to 
ligation of the artery, labeled Annexin A5 was infused. The ligation of the 
left anterior descending artery initiates cell death distal to the site of liga
tion. The animal was sacrificed, and the biotin label attached to Annexin A5 
could easily be detected by immunohistochemical analysis of tissue. 
Dumont et al. showed this model not detects cell death, but can also 
evaluate the efficacy of cell death blocking agenst57. In addition, in vivo 
detection of programmed cell death was possible using fluorescently 
labeled Annexin A5. Detection of Annexin A5 binding to cardiomyocytes 
was achieved using a microscope equipped with a fluorescent module 
(Figure 5). 
 
 
 
 
 
Figure 5: 
Invivo whole heart imaging of mice undergoing ischaemia (I) and reperfusion (R). Images taken 
after 30 minutes of ischaemia and 1 and 8 minutes of reperfusion, respectively. Annexin A5 has 
been labeled with a green fluorescent molecule. Notice the increase in intensity of signal. Via this 
method, the externalization of PS can be monitored in a time dependent manner, allowing real 
time visualization of activation of the cell death program in the beating heart. For full color image 
see page 92. 
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Detecting PS exposure in patients requires the development of an imaging 
tool suitable for noninvasive imaging. This has been achieved using nu
clear medicine technology, as this profession has a long history of molecu
lar imaging. The first method descibed to label annexin A5 radioactively 
was its iodination using 125I 37,75 and later 123I 76. However, due to better 
imaging properties and lower radiation exposure 99mTechnetium (99mTc) was 
selected for labelling of Annexin A5. Labelling can be achieved trough a 
variety of methods4. Using 99mTc Annexin A5, we have shown feasibility of 
detecting pathologic programmed cell death in patients with an cute 
myocardial infarction56 (Figure 6).  
 
 
Figure 6: 
Detection of cell death in a patient with acute myocardial infarction, using technetium labeled 
Annexin A5. The left panel shows perfusion imaging in the acute stage prior to opening of the 
occluded artery. The perfusion defect is used as a measure of the area at risk. The right panel 
shows imaging of the binding of technetium labeled Annexin A5 within the area at risk, indicating 
presence of programmed cell death in the area of infarction. For full color image see page 93. 
MOLECULAR IMAGING OF INFLAMMATION 
Inflammation is an important contributing factor in cardiovascular disease. 
As mentioned above, apoptosis is not the sole contributor to plaque insta
bility. Instead, local inflammation and formation of a large necrotic lipid 
core may render atherosclerotic plaques vulnerable to rupture, Plaque 
rupture then causes the acute vascular syndrome. Autopsy studies have 
shown that vulnerable plaques involve 5080% of the intravascular lumen. 
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In addition, stenosis of more than 80% is usually not associated with plaque 
vulnerability, as these atherosclerotic lesions are mostly organized and 
stable. Therefore, luminography, such as achieved by coronary angiogra
phy, is a far from ideal to detect plaque instability. Instead, molecular 
imaging techniques have been used lately for detection of local inflamma
tion. Such techniques include MRI, PET and SPECT imaging and usage of 
intravascular devices. MRI can employ targeted contast agents such as ultra 
small particles of iron oxide (USPIO’s). USPIO’s are retained in intraplaque 
macrophages, producing a hyperintense signal on MRI imaging77,78. Possi
bly, intravascular magnetic resonance imaging can be used in combination 
with these imaging agents for detailed local information of plaque biology. 
PET imaging of uptake of 18FDG can increase glucose metabolism at the site 
of inflammation. This principle has been used successfully in vulnerable 
plaques in animals and humans. PET 18FDG imaging is a quantifiable tech
nique in imaging carotid artery atherosclerosis. However, high uptake of 
18FDG in myocardium makes coronary imaging difficult to achieve, al
though feasibility has been shown79. SPECT imaging of targeted agents 
involved in plaque instability such as labelled oxidated LDL and labelled 
matrix metalloproteinases (MMPs) have shown feasibility in animal studies. 
To date, clinical studies using these agents are lacking. 
 
Finally, intravascular devices such as intravascular ultrasound (IVUS) and 
optical coherence tomography (OCT), possibly combined with targeted 
imaging agents, can detect local anatomy in great detail. IVUS has been 
used for plaque characterization in coronary atheroma in patients. Al
though highly promising, authors differ in definition of vulnerable IVUS 
characteristics. No prospective studies have been performed linking vul
nerable characteristics to coronary events. Finally, the resolution of IVUS 
(150 to 300 μm) is too low to detect thin fibrous caps (50 to 75 μm). OCT 
does render enough resolution (4 to 20 μm). The technology is analogous 
to ultrasound, measuring the backreflection of infrared light rather than 
ultrasound. Animal studies have shown that OCT of atheroma correlates 
well with pathology specimens. Attenuation by blood and the limited tissue 
penetration may limit the yield of OCT, but can be partially overcome by 
balloon occlusion and saline flushing. Human studies are underway, and 
have thus far shown OCT to be feasible and safe. Indeed, preliminary 
studies have shown feasibility of detecting thin fibrous cap atheroma, a 
highly likely precursor for acute coronary syndromes. More work is under
way identifying macrophage invasion and lipid content, but technical 
obstacles still have to be taken80. 
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BREAKING THE CODE:  
DETECTION OF BIOLOGY UNDERLYING CARDIOVASCULAR DISEASE 
As stated previously, molecular imaging of PS expression provides a feasi
ble target for early detection of cardiovascular disease. In addition, proof
ofconcept has been obtained in patients with an acute myocardial infarc
tion. This thesis aims to provide insights into biology underlying cardiovas
cular disease, focusing on the use of detection of PS exposure. In chapter 
two, we describe the use of radiolabeled Annexin A5 for detection of 
programmed cell death in patients with heart failure. Programmed cell 
death is an integral part of the pathophysiology of heart failure, and detect
ing it could predict clinical outcome and potentially identify patients at risk. 
We selected patients with an idiopathic dilated cardiomyopathy (IDCM), as 
previous studies have shown IDCM patients have a high rate of apoptosis. 
Potentially molecular imaging may select patients that would profit from 
cell death blocking agents. Chapter three illustrates the use of Annexin A5 
imaging in a patient suffering from infectious endocarditis, and discusses 
the potential role of this imaging modality in the diagnostic workup of 
endocarditis. Chapter four shows the use of molecular imaging in detection 
of unstable plaque. Unstable atherosclerotic plaque is characterized by 
macrophage apoptosis, presence of fresh thrombus and macrophage 
activation. As chapters two, three and four shown, all these processes are 
characterized by PS expression, and therefore a target for Annexin imaging. 
Being the precursor to stroke and acute myocardial infarction, detection of 
unstable plaque may provide clinicians with a tool for preventative care, 
selecting high risk patients for invasive procedures. Chapter five demon
strates the use of Annexin A5 imaging in patients with an intracardiac mass. 
Making the diagnosis in these cases is challenging, as intracardiac masses 
are unsuitable for biopsy taking. Thus diagnosis is often made after surgery, 
thereby denying patients optimal treatment. We have aimed to come to a 
diagnosis prior to surgery. This could favorably influence clinical decision 
making. Chapter six will shortly summarize the results of our studies and 
compare them to other imaging techniques. In addition, future possibilities 
are discussed. 
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ABSTRACT 
Apoptosis or programmed cell death (PCD) contributes to the decline in 
ventricular function in heart failure. Since apoptosis comprises a pro
grammed cascade of events, it is potentially reversible, and timely interven
tion should delay the development of cardiomyopathy. 99mTclabeled 
Annexin A5 has been successfully employed for the noninvasive detection 
of PCD in myocardial infarction and heart transplant rejection. The present 
study evaluates the role of Annexin A5 imaging for detection of PCD in 
heart failure patients. 
Methods: Annexin A5 imaging was performed in 9 consecutive heart failure 
patients with advanced nonischemic cardiomyopathy (dilated, N = 8; and 
hypertrophic, N = 1), and also in two relatives of the hypertrophic cardio
myopathy patient having the same genetic background but no heart failure. 
Results: Four patients with dilated cardiomyopathy and one with hypertro
phic cardiomyopathy and heart failure showed focal, multifocal or global 
left ventricular uptake of Annexin A5. No uptake was visualized in the 
remaining 4 patients, and 2 controls. All cases showing Annexin A5 uptake 
within the left ventricle suffered significant reduction in left ventricular 
function and/or functional class. In cases with no Annexin A5 uptake, left 
ventricular function and clinical status remained stable. 
Conclusions: These data indicate the feasibility of noninvasive PCD detec
tion with annexin imaging in heart failure patients. Annexin A5 uptake is 
associated with deterioration in left ventricular function and may lend itself 
to development of novel management strategies. 
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INTRODUCTION 
Heart failure is evolving to be the most important cardiovascular health 
problem 81 and strategies that allow recognition of potentially reversible 
myocardial damage may have significant clinical impact. Heart failure is 
characterized by inexorable deterioration in ventricular function 82, 83. 
Apoptosis or programmed cell death (PCD) of cardiomyocytes has been 
proposed as an important process that mediates the slow ongoing loss of 
heart muscle cells and ventricular dysfunction47. Antiapoptotic interven
tion is known to delay and prevent the occurrence or minimize the severity 
of heart failure in animal models8,9. Since apoptosis is genetically pro
grammed and can be modified, it is important to develop techniques for 
noninvasive detection of PCD in heart failure10. 
Activation of caspase 3, the hallmark of PCD, leads to alteration in phos
pholipid assortment in sarcolemmal lipid bilayer resulting in externaliza
tion of phosphatidyl serine(PS) to the outer surface of the cell membrane11, 
12. PS externalization has been successfully detected noninvasively by 
radionuclide imaging with 99mTclabeled Annexin A513,14. The clinical feasi
bility of imaging with Annexin A5 has been demonstrated in patients 
presenting with acute myocardial infarction13, cardiac allograft rejection15, 
and malignant intramyocardial masses14. We studied the feasibility of 
Annexin A5 imaging for the detection of PCD in a small group of patients 
with advanced heart failure. 
METHODS 
Patients 
Annexin A5 imaging was performed in nine consecutive patients admitted 
with nonischemic cardiomyopathy and advanced heart failure. Ages 
ranged from 3564 years, six of the nine patients were males. New York 
Heart Association (NYHA) class II, III, and IV symptoms were reported by 1, 
5 and 3 patients, respectively. Eight patients had idiopathic dilated cardio
myopathy (#18); four of them (#3,6,7,8) had shown recent worsening of 
failure with a reduction of at least one NYHA functional class during the 
past 3 months. The remaining patient (#9) developed heart failure secon
dary to familial hypertrophic cardiomyopathy caused by a mutation in the 
myosin gene at locus 14q11q12. Two relatives of patient #9 with the same 
myosin gene mutation (ages 33 and 36 years, both females),a hypertrophic 
echocardiographic phenotype and normal LVEF also underwent Annexin 
A5 imaging as hypertrophic but nonfailing controls. Patient characteristics 
are summarized in table 1. 
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Table 1. Patient chararteristics and outcome of Annexin A5 SPECT. 
 
Pt Sex/age Dx NYHA  
prior 
NYHA  
study 
LVEF 
study 
LVEF  
post 
SPECT 
         
1 M/63 DCM III III 25% 30% Negative 
2 M/35 DCM II II 26% 50% Negative 
3 F/39 DCM I III 45% 46% Focal 
4 M/52 DCM III III 31% 34% Negative 
5 M/50 DCM III III 17% 22% Negative 
6 M/58 DCM II IV 48% 24% Focal, mainly lateral 
7 F/64 DCM II III 21% 15% Multifocal 
8 F/41 DCM III IV 20% 22% Negative 
9 F/33 HCM II IV 26% 15% Positive, Diffuse LV 
         
10 F/36 HCM I I 52% N/A Negative 
11 F/37 HCM I I 73% N/A Negative 
Pt = patient number; Dx = diagnosis; DCM = dilated cardiomyopathy; HCM = hypertrophic 
cardiomyopathy; NYHA prior = New York Heart Association functional class prior to study; NYHA 
study = NYHA class at time of study; LVEF study = LVEF at time of Annexin imaging; LVEF post = 
LVEF after one year follow up. SPECT = Outcome of the Annexin A5 imaging study. 
Echocardiography was performed in all patients at the time of imaging. Left ventricular ejection 
fraction (LVEF) was assessed by 2D echocardiography. Tracing of the inner myocardial wall of the 
left ventricle in both enddiastolic and endsystolic phase was performed. Using modified 
Simpson’s analysis 16, we assessed LVEF. Patients were followedup routinely in the cardiology 
department of our hospital as outpatients. LVEF was reassessed by echocardiography after one 
year in all patients except the hypertrophic controls. 
 
Annexin A5 Labeling and SPECT Study Protocol: 
Human recombinant Annexin A5 (Theseus Imaging Corporation, Boston, 
MA) was labeled with 1 GBq of 99mTc for imaging. Six hours prior to imag
ing, 99mTcAnnexin A5 was administered intravenously. In addition, 32 to 48 
MBq of 201Tl was administered 30 minutes before imaging. All scintigraphic 
studies were performed using a MultiSPECT2 dualhead gamma camera 
(Siemens, Hoffman Estate, IL). A dual isotope imaging protocol was used to 
acquire 99mTc and 201Tl data simultaneously. For 99mTc data, an energy peak 
of 140 keV with a window of 10% was used. 201Tl data were acquired using a 
peak of 166 keV and 70 keV and windows of 15% and 20%, respectively. We 
used a 64×64 matrix and 64 angled views, counting each angle for 60 sec
onds. Studies were reconstructed with a backprojection method. Standard 
views of the left ventricle were constructed using the 201Tl dataset. Limits 
and orientation of the left ventricle were transferred onto the 99mTc
Annexin dataset. Because of simultaneous acquisition of these data, we 
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were able to precisely localize myocardial uptake of 99mTcAnnexin A5. 
Radiation exposure was calculated to between 3.4 to 4.5 mSv. Two readers 
(GH, IL), blinded to clinical information, assessed SPECT data independ
ently. This study complies with the declaration of Helsinki, and was ap
proved by the institutional review committee of the University Hospital of 
Maastricht. All subjects gave written informed consent. 
RESULTS 
Patients #19 had advanced heart failure due to nonischemic cardiomyopa
thy. Prior to entering the study, the absence of coronary artery disease was 
confirmed by coronary angiography. Echocardiography did not show 
regional wall motion abnormalities as determined by standard 2D echo. 
LVEF ranged from 15 to 31% at time of Annexin A5 imaging. LVEF in two 
controls subjects was 52% and 73%, respectively. 
Of the nine CHF patients, five showed Annexin A5 uptake in the left ven
tricular myocardium; no uptake was observed in the right ventricle. The 
uptake was focal in one patient (#6), multifocal in two (#3, 7) (Figure 1A), 
and diffuse in one patient (#9) (Figure 1B). Myocardial perfusion was essen
tially normal in these patients and the areas of Annexin A5 uptake did not 
correspond to a single coronary territory as often observed in myocardial 
infarction. All 4 dilated cardiomyopathy patients with positive Annexin A5 
uptake had sustained significant recent worsening or recent onset of heart 
failure in the last 3 months. Similarly, the patient with the myosin gene 
mutation demonstrated a positive, diffuse uptake and had experienced a 
substantial decrease in LVEF in the past 6 months. 
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Figure 1: 
Dual isotope imaging using 201Tl imaging for LVcontour detection and simultaneous imaging of 
radiolabeled Annexin A5 in patients with dilated cardiomyopathy (DCM). SAX: Short axis LAX: 
Long axis 201Thal: 201 Tl Anx: 99mTc labeled Annexin A5. A: DCM patient with rapid deterioration 
of LV function. Note the focal uptake in the apex and lateral wall, and slight septal uptake. B: 
DCM patient in acute heart failure. Note the global uptake of radiolabeled Annexin A5. C: DCM 
patient in stable clinical condition. Note the absence of uptake, even when the image is en
hanced to the extent that background radioactivity can be observed. D: control case. 
 
 
The remaining four heart failure patients did not show uptake of the radio
tracer (Figure 1C). These patients had poor LV function (LVEF = 25 to 31%) 
but had no recent evidence of worsening of heart failure. The 2 family 
members of HCM patient, with the myosin gene mutation and echocardio
graphic evidence of LV hypertrophy and preserved LVEF did not show 
radiolabeled annexin uptake (Figure 1D). 
During follow up of one year the four patients with positive Annexin A5 
uptake, on average, showed a decline in LVEF. On the other hand in the 
Annexin A5 negative cases LVEF remained stable or increased somewhat 
after one year of follow up. Figure 2 depicts the change in ejection fraction, 
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subtracting LVEF at time of imaging from LVEF one year after imaging. 
Student T testing for paired samples shows a significant difference between 
patients with positive and negative Annexin A5 scan (p= 0.038). 
 
 
 
Figure 2: 
Change in left ventricular ejection fraction one year after Annexin imaging. Green bar shows 
patients with a negative scan (mean EF increase 7%), red bar shows patients with a positive scan 
(mean EF decrease 10%). P = 0.038.  
DISCUSSION 
Apoptosis in Heart Failure: 
PCD contributes to slow ongoing myocardial dysfunction in heart failure 17. 
It has been demonstrated that cytokinemia and ischemic/oxidative stress 
lead to release of cytochrome c from the mitochondria into the cytoplasmic 
compartment and lead to activation of caspase 318. Active caspase 3 cleaves 
contractile proteins and activates DNA fragmentation enzymes. The loss of 
cytochrome c (hence the loss of energy production mechanism in mito
chondria) and the fragmentation of contractile proteins contribute to 
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decline in left ventricular function. Activation of caspase 3 also results in 
scrambling of cell membrane phospholipds, expression of PS (target for 
annexin imaging). However, there is simultaneous activation of various 
antiapoptotic factors in the failing myocardium that inhibit caspase medi
ated activation of DNAses. Such protective steps represent the survival 
instinct of the apoptotic myocardium and result in interruption of the 
apoptotic process1921. The more the antiapoptotic factors, the better 
should be the survival of cardiomyocytes. On the other hand, more activa
tion of caspase 3 results in more PS exposure, and presumably in a worse 
prognosis. 
Noninvasive imaging PCD 
Radionuclide imaging targets cell surface alterations to noninvasively 
recognize various forms of cell death associated with cardiovascular dis
eases 13,15,22. Myocardial necrosis is characterized by a loss of sarcolemmal 
integrity, with the cell membrane allowing free access to radiotracers such 
as glucarate (binding to positivelycharged histones in the disintegrating 
nuclei) and antimyosin antibody (binding to fragmenting insoluble heavy 
chain myosin molecules)23. On the other hand, the sarcolemma remains 
intact in PCD, but the asymmetry of the phospholipid distribution in lipid 
bilayer of the membrane is lost 24. As such, abundant PS is exteriorized to 
the outer surface of membrane that serves as a marker for macrophage 
phagocytosis 24. An endogenous protein, Annexin A5, has high affinity for 
PS, and has therefore been successfully used for the detection of PCD in 
vivo13, 22. PS exposure is closely linked to the activation of the executioner 
caspase 3 and can be prevented by administration of caspase inhibitors25. 
These cell death inhibitors have been shown to reduce the extent of myo
cardial damage in various myocardial pathologies 8,25. The present study 
confirms the feasibility of Annexin A5 imaging for the detection of PCD in 
heart failure patients. Annexin A5 uptake was seen predominantly in those 
patients who had demonstrated a recent worsening in their LV function 
and/or functional class. In addition, these patients on average continued to 
show a decrease in LVEF up to one year in follow up (Figure 2).  
Other Noninvasive Imaging Studies in Heart Failure 
Previous imaging studies for detection of cell death in heart failure have 
been performed using antimyosin antibodies, showing evidence of myo
cardial necrosis in such patients 23, 26. Patients with positive antimyosin 
uptake were shown to have a high likelihood of myocarditis or evidence of 
non inflammatory myocyte degeneration in their endomyocardial biopsy 
samples. Patients with positive antimyosin scans showed functional impro
vement over time in contrast to those with negative antimyosin scans. The 
functional improvement in antimyosinpositive patients appears to be 
counterintuitive. It was proposed that the antimyosinpositivity in dilated 
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cardiomyopathy merely represented the extent of acute myocardial insult 
and the accompanying irreversibly damaged, antimyosinnegative myocytes 
were responsible for functional resolution 23. This is in contrast to Annexin 
A5 imaging, where annexinpositive patients continue to sustain a decrease 
in LV function, and those with negative scans improve their LV function. 
We can only surmise that the antimyosin positive cells were an indirect 
marker of reversible cells, whereas the annexinpositive cells represent the 
true state of balance of proapoptotic and antiapoptotic factors in the 
cardiomyocytes, and should be more predictive of prognosis. It is apparent 
that the cells with lower amount of antiapoptotic factors (hence more PS 
expression and Annexin A5 positivity) would be better candidates for 
exogenous antiapoptotic therapy. These findings have been translated into 
figure 3.  
Limitations of the Study 
These data should be interpreted carefully because of inclusion of a small 
number of patients. Further prospective trials including larger number of 
dilated cardiomyopathy patients with sequential scans and functional 
follow ups may clarify the current observations. As 201Tl gamma photons 
also have energy peak at 166 keV, there may be some downscatter into the 
140 keV window of 99MTc. However, this downscatter was not observed in 
the family members of the HCM patient (Figure 1D). In addition, we did not 
observe downscatter in patients included in other studies (unpublished 
data). Furthermore, Annexin A5 uptake is focal in most patients, whereas 
downscatter from 201Tl should appear throughout the left ventricle. Endo
myocardial biopsies were not performed in the present study. As biopsies 
are not likely to influence management strategy, the ethical committee did 
not allow the biopsies for the research purposes and for mere comparison 
with the results of Annexin A5 scans. In addition, serial Annexin A5 scans 
were also not allowed. The lack of endomyocardial biopsies precludes the 
diagnosis of myocarditis in scanpositive patients. Since none of the scan
positive patients showed improvement of LVEF, the likelihood of myocardi
tis in those cases is low. 
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Figure 3: 
Cytokine and oxidative stress (ROS) in heart failure lead to caspase 3 activation by release of 
cytochrome c from mitochondria into cytoplasmic compartment. Activation of caspase 3 results in 
cytoplasmic proteolysis and DNA fragmentation, and hence apoptosis. Endogenous upregulation 
of BCl2 and XIAP like proteins and loss of DNA fragmentation factors prevent completion of 
apoptotic process (apoptosis interruptus). The amount of activated caspase 3 is determined by 
the balance of antiapoptotic and proapoptotic factors. Less the endogenous antiapoptotic 
factors, more is residual caspase, more PS externalization, higher the likelihood of annexin
positive scan, poorer prognosis and higher necessity for apoptosis inhibition therapy. 
 
Conclusion 
This proof of principle study suggests that Annexin A5 imaging may identify 
accelerated myocardial cell loss in nonischemic dilated cardiomyopathy 
patients with recent worsening of heart failure. Such strategy may offer a 
new possibility to study interventions aimed at minimizing the progression 
of myocardial dysfunction.  
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A 54 year old woman presented to our hospital after an episode of fever of 
unknown origin. The fever had occurred 6 weeks prior to presentation, and 
subsided spontaneously. The patient had no relevant prior medical history. 
When presenting to our first aid, she suffered from mild dyspnea. No fever 
was recorded at the time of presentation. Physical examination revealed 
normal blood pressure, an elevated central venous pressure, crepitations 
on both lungs and peripheral edema. In addition, a holosystolic murmur 
was heard on the apex. Echocardiography was performed, showing mitral 
regurgitation and a mass attached to the mitral valve (see figure 1A). Blood 
cultures were taken and an Annexin A5 scan was performed. The bloodcul
tures showed streptococcus milleri after 9 days of incubation. In spite of 
adequate antibiotic treatment, patient developed increasing signs of con
gestive heart failure and was sent for mitral valve replacement after 2 weeks 
of antibiotics. After surgery valvular tissue was stained for presence of 
Annexin A5 and macrophages. 
 
Using a dual isotope technique, we were able to localize Annexin A5 
uptake in relation to the left ventricle. SPECT showed intense uptake of 
Annexin A5 in the area of the mitral valve (Figure 1C). The valvular tissue 
showed abundant Annexin A5 binding. Annexin A colocalized with CD68 
staining, a macrophage marker (Figure 1B). The Annexin A5 scan thus 
predicted infective endocarditis 8 days prior to bloodcultures becoming 
positive. 
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Figure 1: 
A: Transthoracal echocardiography, parasternal long axis view of the left ventricle. Arrowhead 
depicts mass attached to the mitral valve. Ao = Aorta; LV = Left ventricle. B: Immunohistochemis
try of the intracardiac mass. Brown staining = Annexin A5. Upper panel shows extensive binding 
of Annexin A5 to cell membranes. Lower panel shows colocalisation of a macrophage marker 
(CD68, dark blue staining), and Annexin A5. C: Dual isotope imaging using 201TL and 99mTc 
Annexin A5. Arrowheads point to Annexin A5 uptake in the area of the mitral valve. For full color 
image see page 94. 
 
DISCUSSION 
Infective endocarditis (IE) remains an important clinical problem, having 
relatively high morbidity and mortality if not treated aggressively. The 
incidence rate ranges from 1.7 to 6.2 cases per 100,000 in a general popula
tion and has remained essentially unchanged in the last two decades, 
despite advances in therapy. This can largely be explained by a shift in risk 
factors predisposing for IE. Novel populations at risk include hemodialysis 
patients, patients exposed to nosocomial infections, intravenous drug users 
and increasing incidence of highly sclerotic valves in the elderly patients 
and increased use of prosthetic valve. These patient groups have all but 
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replaced patients with classic risk factors such as rheumatic heart disease. 
The diagnosis of IE is based on Duke classification, using criteria such as 
positive bloodcultures, vegetations detected on echocardiography, fever, 
presence or absence of predisposing heart disease, occurrence of new 
valvular murmur and signs of distant embolization1. Although extremely 
useful in IE in native valve disease, these criteria have not been evaluated in 
prosthetic valve IE or IE in hemodialysis patients, hospitalized patients or IV 
drug users. Hence making the diagnosis of IE is often difficult, but all the 
more important since early effective treatment prevents tissue destruction 
and thus improves clinical outcome. Although not present in all cases of IE, 
valvular destruction often necessitates valvular replacement surgery. Often, 
timing of valvular surgery is difficult. Although evidence of distant emboli
zation of infective fragments is an indication for early surgery, surgeons 
prefer insertion of a prosthetic valve in noninfected tissue. Usually, antibi
otic treatment is carried on for 6 weeks after diagnosis of IE. Finally, echo
cardiography cannot reliably differentiate florid vegetations from residual 
structural changes of the affected valves in cured patients, thereby intro
ducing the risk of unnecessary treatment. 
 
Imaging modalities such as echocardiography or MR can inform us about 
size, shape and heamodynamic consequences of IE, but are unable to 
evaluate lesion biology. However, molecular imaging technology can 
provide biological information. Hence, nuclear imaging techniques have 
been used for detection of IE. Detection of leukocyte invasion using In111
leucocyte scanning has limited sensitivity, rendering it less useful for 
clinical practise. Gallium67 is taken up by leucocytes and bacteria. In 
addition, it may bind to bacterial surface molecules2. Gallium SPECT imag
ing thus may be useful in detecting IE, although no trials have been per
formed. Inflammation can also be imaged by PET FDG imaging, but cardiac 
imaging using FDG has the disadvantage of a high background signal. 
Finally, platelet activation is widely present in IE. This feature has been 
employed for detection of IE using a radiolabeled gpIIb/IIIa inhibitor3. 
 
We and other groups have shown the use of radiolabeled Annexin A5 
imaging in detection of phosphatidylserine (PS) exposure4, 5. Macrophages 
involved in phagocytosis expose PS at the site of engulfment of bacteria 
and cellular fragments6. Secondly, activated platelets expose PS to their 
surface, creating another imaging target7. Thirdly, PS is the hallmark of cell 
undergoing programmed cell death8. Programmed cell death is seen in IE at 
the site of valvular destruction, macrophage apoptosis after engulfment of 
bacteria and debris and bacterial PCD, thereby creating targets for Annexin 
A5. We therefore propose that PS exposure is abundant in IE creating a 
novel opportunity for IE detection using Annexin A5 imaging. 
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This case report shows feasibility of detection of PS exposure in IE. Al
though the clinical picture was suggestive of IE, bloodcultures did not show 
a pathogen up to 9 days. Annexin A5 imaging however, showed uptake of 
the radiopharmacon on the day of admission. Annexin A5 bound mainly to 
macrophages, but also to fibroblasts and activated platelets. In conclusion, 
Annexin A5 imaging may be useful in clinical practise for early diagnosis of 
IE, evaluation of treatment and timing of surgery, possibly improving 
outcome. Further studies are needed to assess these questions. 
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INTRODUCTION 
Although the progressive stenosis of the arterial lumen constitutes the 
basis of ischemic symptoms in atherosclerotic vascular disease, the acute 
vascular events are not necessarily associated with severely occlusive 
lesions1. In up to twothirds of the patients with acute coronary syndromes, 
the acute event results from plaque rupture and formation of an occlusive 
thrombus2. Vulnerability of the atherosclerotic plaque to rupture is associ
ated with distinct histopathologic characteristics including large lipid core, 
attenuated fibrous cap and inflammatory cell infiltration of the cap3. It is 
being increasingly recognized that apoptosis of various cellular compo
nents in atherosclerotic plaques contributes to plaque vulnerability. Apop
tosis of smooth muscle cells leads to progressive thinning of fibrous cap, 
and that of macrophages leads to enlargement of lipid core4. Also, apop
tosis of macrophages in the fibrous cap has been causally linked to plaque 
rupture5. 
Several diagnostic methods have attempted to evaluate unstable plaques. 
Such techniques include MRI detection of thin fibrous caps and that of 
ferrous oxide particlerich macrophagepopulation or detection of inflam
matory foci in plaques by thermography catheters. We have previously 
demonstrated that apoptosis can be imaged non invasively in experimental 
atherosclerotic plaques using radiolabeled AnnexinA5 6,7. AnnexinA5 is 
plasma protein, which shows strong affinity for phosphatidyl serine, ex
posed by apoptotic cells. In the present study, we investigated the feasibil
ity of clinical utility of Annexin imaging in 3 patients with 3day to 3month 
old transient ischemic attacks (TIA), who were scheduled for carotid en
darterectomy. 
METHODS 
Four patients that were scheduled for carotid endarterectomy were imaged 
one to three days prior to surgery using 99mTechnetium (99mTc) labeled 
Annexin A5 (Theseus Imaging Corporation, Boston, MA). All patients had 
suffered from a transient ischaemic attack (TIA) due to an atherosclerotic 
lesion in their internal carotid artery. Of the four cases, two had suffered 
from a TIA in their right hemisphere 3 and 4 days prior to imaging, respec
tively. The other two cases had experienced symptoms 3 months prior to 
surgery. All patients received a dose of 600 to 800 MBq of 99mTc labeled 
Annexin A5. Patients were imaged 6 hours after infusion of labeled Annexin 
A5, using a multiSPECT dual head gamma camera (Siemens, Hoffman Estate, 
IL); 64 angled views were obtained for 60 seconds each. Data were recon
structed using a back projection method by means of a butterworth filter. 
Before surgery, a Dopplerultrasound study was performed. The endarter
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ectomy specimens retrieved during surgery were embedded and stained by 
H&E and Movat’s pentachrome stains. Direct immunohistochemical stain
ing was performed to localize the binding of Annexin A5. 
RESULTS 
Two patients who had suffered from a recent TIA showed distinct uptake of 
radiolabeled Annexin in the area of the right carotid artery lesion; the area 
of uptake corresponded to the ultrasonically verified stenotic lesion. 
Interestingly, preoperative Dopplerultrasound study in one patient with 
recent symptoms had demonstrated similar degree of stenosis in the 
contralateral carotid artery, but no Annexin uptake was observed (Figure 
1A). The two cases that had sustained TIA 3 months prior to imaging 
showed no uptake in the carotid artery on the affected side (Figure 1B). 
Doppler ultrasound had showed significant stenoses in these two patients. 
Analysis of endarterectomy specimen from the patients with positive 
imaging results showed unstable plaque morphology, including a thin 
fibrous cap that harbored significant macrophage infiltration. On immuno
histochemical analysis, Annexin binding was predominantly observed on 
the cell membranes of macrophages at the shoulder of the unstable 
plaque; some staining was also seen in fibroblasts and vascular smooth 
muscle cells (Figure 1C). The endarterectomy specimens from the two 
patients with remote TIA and no Annexin uptake revealed thick fibrous 
caps and a small lipid core in their atherosclerotic plaques indicating stable 
plaque characteristics; no Annexin binding was observed, as shown in 
figure 1D.  
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Figure 1 : 
Annexin A5 imaging of carotid artery atherosclerosis. Panel A: Annexin imaging in a patient with 
recent TIA. Note enhanced uptake in the left carotid artery region (arrowheads). Panel B: Unstable 
atherosclerotic plaque and Annexin binding to cell membranes, mainly macrophages. Panel C: 
Annexin imaging in remote TIA, no enhanced uptake is observed. Panel D: Stable atherosclerotic 
plaque, absence of Annexin A5 binding to cells. For full color image see page 95. 
 
DISCUSSION 
This preliminary study for the first time demonstrates the feasibility of 
identification and localization of unstable carotid artery lesions in patients 
with targeted molecular imaging technology. In the patient with recent TIA, 
high Annexin uptake on SPECT imaging suggests the presence of unstable 
plaque. Immunohistochemical analysis revealed Annexin uptake within the 
macrophage infiltration in atherosclerotic plaques. In the same patient, a 
similar degree of carotid artery stenosis on the contralateral (unaffected) 
side did not show any Annexin uptake. In addition to the feasibility of 
concept of imaging vulnerable atherosclerotic plaque, the study reaffirms 
that the vascular wall biology of an atherosclerotic lesion is the major 
determinant of vulnerability rather than the degree of stenosis. In addition, 
localization of Annexin within the macrophages subjacent to thin fibrous 
cap further supported the inflammatory hypothesis of plaque rupture5. In 
the two negative cases, there was a delay of 3 months between the TIA and 
the imaging or surgical intervention. Histopathological analysis of these 
Recent TIA
A
B
3 month old TIA
C
D
ANT
L
Transverse
Coronal
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specimens demonstrated stable plaque morphology consonant with nega
tive Annexin SPECT images. These data suggested that the cell death in the 
plaque was no longer present, which may indicate stabilization of the 
lesion. Experimental studies have demonstrated that the statin therapy 
decreases the Annexin determined prevalence of apoptosis in atheroscle
rotic plaques by approximately onehalf. However, since statins may take at 
least 4 weeks for efficacy in the plaque stabilization8, one might speculate 
that intervention in the cell death program to prevent macrophage apop
tosis may offer a novel approach to stabilization of the atherosclerotic 
lesions in acute phase. Thus this study opens a new avenue of diagnostic 
imaging modality in unstable plaques, and provides a basis for provocative 
therapeutic strategy in the management of acute vascular event. 
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CHAPTER 5 
The diagnosis of intracardiac masses: 
absence of Annexin A5 uptake 
indicates favorable prognosis. 
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ABSTRACT 
Purpose: Endocardial masses pose a diagnostic dilemma. Prognosis and 
treatment greatly depend on the biological nature of the mass. Due to high 
risk of embolic complications, biopsy taking from intracardiac masses is 
clinically not employed. Current imaging technology can depict size, shape 
and location, but fails to differentiate benign from malignant intracardiac 
masses. 
Experimental Design: We evaluated 15 consecutive cases presenting to our 
department with an unknown cardiac mass. All patients were subjected to 
SPECT imaging using radiolabeled Annexin A5. 8 Patients were operated 
upon, enabling diagnosis by histology. Patients in whom surgery was not an 
option underwent followup echocardiography. 
Results and conclusions: Eleven patients with a negative scan showed 
either benign tumor at surgery or no growth at three years follow up. 
Negative Annexin A5 scans were therefore associated with a favourable 
outcome. Positive scans showed malignant tumor, endocarditis or fresh 
intracavitary thrombus, associating Annexin A5 positivity with poor out
come. These data indicate that Annexin A5 imaging may have incremental 
diagnostic value in patienst presenting with an unknown intracardiac mass. 
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INTRODUCTION 
Intracardiac masses are not too commonly seen1. They may, however, have 
dire consequences. The diagnosis of these masses has been based on their 
echocardiographically defined location, mobility and appearance. These 
masses often comprise tumors, thrombi and infectious processes. Subsets 
of these lesions may have significantly poor outcome such as that associ
ated with fresh unorganized thrombi, malignant tumors and infected 
vegetation. Therefore, in addition to an anatomical diagnosis, it is important 
to obtain biological characteristics. Most patients presenting with a tumor 
in one of the intracardiac cavities turn out to have a metastatic tumor. The 
incidence of primary cardiac tumors is difficult to assess, but postmortem 
studies indicate that 0.01% to 0.3% of patients have an intracardiac tumor at 
autopsy2, 3. Malignant cardiac tumors comprising between 5.5 to 10 % of all 
primary cardiac tumors in surgical studies1,2. In autopsy studies, up to 25% 
of primary cardiac tumors are malignant1,2,46. Malignant primary cardiac 
tumors are sarcomas in more than 95% of the cases, of which angiosarcoma 
is the most common. Whereas benign intracardiac tumors carry an excel
lent survival rate, malignant intracardiac tumors have a very poor progno
sis. Finally, a fresh left ventricular thrombus developing in the context of a 
poor LV function, carries a high risk of thromboembolic complications. 
Thus, obtaining information on the nature of the intracardiac mass prior to 
medical treatment or surgery is imperative to define the best therapeutic 
strategy in an individual patient. 
Conventional techniques such as echocardiography, CT or MRI give insight 
in the anatomy of cardiac tumors. However, they do not reveal biological 
information about these tumors, such as the benign or malignant makeup. 
Thus, making a definite diagnosis is often difficult if not impossible to make 
until histological examination of the resected tumor has been performed8, 
since biopsy taking of an intracardiac mass carries a high risk of embolic 
complications. Only in selected cases a biopsy of a metastatic skin lesion 
will reveal the nature of the intracardiac mass. 
 
Noninvasive biological imaging such as positron emission tomography of 
18Fluordeoxyglucose (PETFDG) has been used to assess the nature of 
tumors, discriminating malignant tumors by the amount of glucose me
tabolism. The disadvantage of the use of PET imaging to identify intra
cardiac lesions is hampered by the high background signal in cardiac 
imaging. An alternative strategy to obtain information on the biology of 
intracardiac tumors is to make use of targeted imaging agents. Annexin A5 
binds to phosphatedylserine (PS) which is exposed by the cell membrane 
of cells undergoing programmed cell death9. Our group and others have 
shown the clinical use of radiolabeled Annexin A5 in detecting pro
grammed cell death10,11. One of the biological differences between malig
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nant and benign lesions is the rate of cell death12. Histopathological stud
ies have shown that the extent of cell death in a tumor increases with the 
rate of malignancy. We previously showed feasibility of detecting cell death 
in an intracardiac malignant tumor13. Finally, Annexin A5 can be used for 
detection of fresh intracavitary thrombus in animals15. We hypothesize that 
molecular imaging using radiolabeled Annexin A5 allows noninvasive 
assessment of the biology of intracardiac masses in patients, and, therefore, 
supports diagnosis and management of therapy. 
MATERIALS AND METHODS 
Patient characteristics 
We evaluated 15 patients with an unknown intracardiac mass tumors who 
presented to our and 3 referring centers within the period of one year. Age 
ranged from 15 to 92 years. In all cases the diagnosis of an intracardiac mass 
was made by echocardiographic analysis. Patient characteristics are pre
sented in table 1. Some patients were not operated upon due to various 
reasons, all stated in table 1. If a patient is classified inoperable, this indi
cates a clinical status too poor for cardiac surgery because of concomitant 
disease. This study was carried out in accordance to the declaration of 
Helsinki. All patients signed informed consent. The study was approved by 
the university hospital of Maastricht ethical committee. 
Non invasive imaging with 99mTechnetium labeled Annexin A5 
Patients referred for cardiac surgery were imaged the day prior to surgery. 
Human recombinant Annexin A5 was labeled with 900 to 1000 MBq 
99mTechnetium (99mTc) using a Hynic bridge (Apomate, Theseus Imaging 
Corporation, Boston, MA, USA). Radiochemical purity varied from 90 to 97 
percent. The labeled Annexin A5 was infused 46 hours prior to imaging. 30 
Minutes prior to imaging, 60 to 65 MBq 201Thallium (201Tl) was infused. 
Scintigraphic imaging was done using a multiSPECT 2 gamma camera 
(Siemens, Hoffman Estate, IL, USA). A dual isotope imaging protocol was 
used, acquiring the 99mTc and 201Tl data simultaneously. We used an energy 
peak of 140 keV with a window of 10% for the 99mTc data. For the 201Tl data 
an energy peak of 60 keV with a window of 10% and a peak of 167 keV and a 
window of 15 % were chosen. We used a 64 by 64 matrix and 64 angle 
views, counting each angle for 60 seconds. Studies were reconstructed 
using a back projection method by means of a Butterworth filter with a cut
off frequency of 0,55 and an order of 5. Standard views of the left ventricle 
were reconstructed using the 201Tl dataset. The 99mTc dataset was recon
structed in using the same limits and orientation, which allowed us to relate 
the possible Annexin A5 uptake to the position of the left ventricle. One 
patient was imaged using a SPECT/CT device in a referring hospital (Infinia 
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Hawkeye; GE healthcare, Waukesha, WI, USA). A similar dose, timing and 
energy settings were used for the SPECT images of radiolabeled Annexin 
A5. The CT images were used for anatomic reference. Fusion of the An
nexin A5 dataset onto the CT images enabled localization of Annexin A5 
uptake. Images were assessed by two blinded observers (IL, GH). 
Histopathologic and immunohistochemical analysis of specimens 
Surgical removal of the intracardiac mass was performed in 8 cases. Tissue 
was obtained from all these excised masses and embedded. All tissue 
sections were characterized using standard H&E (hematoxiclineosin) 
staining and anti Annexin A5 staining as described previously16, using 
polyclonal antiannexin A5 rabbit antibody (Hyphen Biomed). 
RESULTS 
In 14 out of 15 patients the intracardiac mass was diagnosed using echocar
diography. Typical examples of the echocardiographic presentation of an 
intracardiac mass are found in figure 1, panels IA trough IC. In the remain
ing patient the diagnosis was done by means of SPECT/CT imaging, as 
shown in figure 2. Of the entire group of patients (n=15), eleven patients 
showed a negative Annexin A5 scan. A typical example is shown in figure 1, 
panel IB. Six of the patients with a negative scan were operated upon. 
Histology showed typical myxoma in all 6 cases, such as shown in figure 1, 
panel IC. The presence of clustering of nuclei and a large extent of extracel
lular matrix are diagnostic for cardiac myoxoma. Immonuhistochemistry 
showed a very low number (<0.01%) of cells binding Annexin to their cell 
surface. The remaining five cases with a negative Annexin A5 SPECT pa
tients did not undergo surgery, and were followed by repeat echocardi
ography. No increase in size or embolic complications were seen during a 
mean followup of 3 years (range 2 to 5.2 years). 
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Figure 1: 
Molecular and anatomical imaging of intracardiac masses. 
Panel IA shows a parasternal long axis view of the left ventricle. There is a clear intracardiac mass
shown in the area of the mitral valve. Panel IB shows a normal perfusion image of the left
ventricle (short axis view). Note the absence of uptake of annexin A5 in the same region. Panel IC 
shows histology, no Annexin A5 staining was observerd. 
Panel IIA shows a parasternal long axis view of the left ventricle with a large mass attached to the
left ventricular wall. Panel IIB shows intense uptake of radiolabeled Annexin A5 in the region of 
the left ventricle. Panel IIC confirms binding of annexin A5 to cells (brown staining). Histology
showed sarcoma 
Panel IIIA is a cardiac magnetic resonance image. This four chamber view shows a large mass
attached to the LV apex in the presence of an apical infarct. Panel IIIB shows uptake of radio
labeled Annexin in the area of the LV apex in the left panel. Right panel shows a fusion image
between low resolution CT and nuclear imaging, confirming the localization of the Annexin
uptake (LV apex). In this case no cardiac surgery was performed. For full color image see page 96. 
 
 
Three patients showed uptake of 99mTc labeled Annexin A5 within the area 
of the left ventricle. A typical example is shown in figure 1, panels IIB and 
IIC. Two of these patients were operated upon. In one of the positive 
patients, slight complaints and near collaps were present. In this case, 
echocardiography showed a large mass in the left ventricular cavity (Figure 
1; panel IIA). The histologic analysis of the surgically removed tumor speci
men showed undifferentiated sarcoma. In addition, staining for Annexin A5 
was performed, showing abundant binding of Annexin A5 to the plasma 
membranes of tumor cells (Figure 1; panel IIC). A further positive scan was 
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made in a patient that had suffered a large anterior wall myocardial infrac
tion prior to presentation. Echocardiography showed very slow flow in the 
left ventricular apex, and a mass with a broad base attached to infarcted 
myocardium. MRI also showed a left ventricular mass at the apex (Figure 1 
panel IIIA). SPECT/CT imaging displayed uptake of radiolabeled Annexin in 
the left ventricular apex (Figure 1, panel IIIB). Finally, one patient (pt #1) 
with an intracardiac mass arrived in our hospital in severe cardiac failure 
due to obstruction of almost the entire right atrium by tumor mass. She was 
referred for emergency surgery. PA diagnosis showed osteosarcoma, and 
abundant binding of native (endogenous) Annexin A5 to tumor cells. The 
extent of binding and size of the tumor was similar to that of patient #3. 
 
On immunohistochemical analysis, the apoptotic index (cells expressing 
PS/ total number of cells) was below 0.01 in the tumor specimens of pa
tients with a negative Annexin A5 SPECT. The apoptotic index was above 0.4 
(0.41 and 0.52, respectively) in the two patients with a positive SPECT with a 
primary malignant intracardiac mass. In our dataset, the apoptotic index 
correlated well with degree of malignancy. 
 
Panel IIIA shows MRI image of the left ventricle. Note the large mass at
tached to the left ventricular apex. Panel IVB shows uptake of radiolabeled 
Annexin A5 at the area of the left ventricular apex. The image on the right 
shows fusion of the MRI data with the Annexin A5 SPECT data, confirming 
that the uptake is localized at the left ventricular apex. No surgery was 
required in this patient. 
DISCUSSION 
Our data indicate that molecular imaging, using radiolabeled Annexin A5, is 
feasible and safe in patients presenting with an unknown intracardiac mass. 
The imaging results correlate well with Annexin A5 binding to cells on 
histology. More importantly, we show that absence of uptake Annexin A5 
uptake in the intracardiac mass as found on SPECT imaging, indicates a 
benign origin of the intracardiac lesions. In all patients with a negative 
Annexin A5 SPECT scans in whom the intracardiac mass was surgically 
removed histologic examination showed the typical features of myxoma . In 
patients with a negative Annexin A5 SPECT in whom surgery was not per
formed, no growth of the intracardiac lesion was observed and complete 
absence of complications during 3 year followup. Taken together, these 
data indicate that a negative Annexin A5 SPECT is strongly associated with 
favorable outcome in patients with unknown intracardiac masses. 
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Positive scans were seen in patients with malignant intracardiac tumor and 
fresh intracavitary thrombus. In malignant tumors, Annexin A5 binds to 
apoptotic cells externalizing phosphatidylserine (PS). This is in accordance 
with the literature, as it has been reported that a higher rate of pro
grammed cell death in tumors correlates with more aggressive tumors and 
rapid metastasis12. Secondly, Annexin A5 bound to externalized PS in fresh 
thrombus. Rapid PS exposure is seen in platelets stimulated by thrombin 
and collagen18,19. Exposed PS is essential for assembly of active prothrombi
nase20, and plays a role in activation of prothrombin21. Detection of PS 
exposure has been used to detect fresh cloth in porcine left atrial throm
bus15. 
 
These data confirm feasibility of studying biology of masses not suitable for 
biopsy taking. Moreover, Annexin A5 imaging can be performed using 
widely available SPECT technology. In contrast with PET18FDG, Annexin A5 
imaging does not suffer from high background radiation in the area of the 
heart, improving image quality and ease of interpretation in this area. 
Potentially the response of masses to treatment could be monitored using a 
sequential imaging approach, as has been suggested in trials evaluating 
success of treatment in nonHodgkin lymphoma22, providing additional 
information in areas with high PET background noise. This new technique 
of molecular imaging of programmed cell death may prove to be a valuable 
addition to the more conventional noninvasive techniques, and can pro
vide important clues as to the nature of the mass. Due to the low number 
of patients, our study is insufficiently powered for stating that positive 
scans are always indicative of malignancy. We conclude that patients with 
an intracardiac mass and a positive Annexin A5 SPECT should undergo an 
aggressive diagnostic and therapeutic approach. Furthermore, patients with 
a positive Annexin A5 SPECT and absence of fever or conditions enabling 
thrombus formation, malignancy should be suspected. 
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General discussion  
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Clinical syndromes such as the acute coronary syndrome, stroke or devel
opment of congestive heart failure are often the first manifestation of 
cardiovascular disease in previously asymptomatic patients. These patients 
have suffered from subclinical disease prior to clinical events. Identification 
of patients at risk for these syndromes is therefore an important goal in 
clinical medicine1. In addition to classical risk factors, it has become in
creasingly clear that insight into molecular mechanisms leading up to these 
clinical syndromes can help identify high risk patients. In addition, inter
vention in such mechanisms can aid in preventing such events from occur
ring. Finally, monitoring these biological mechanisms may aid in evaluating 
success of treatment, or warrant a more aggressive treatment strategy. In 
recent years, measuring biomarkers in serum such as high sensitive C
reactive protein2,3 and Nterminal probrain natriuretic peptide4 has com
plemented classical risk factors in identification of patients at risk. Although 
useful to further riskstratify patients, their incremental value to predict 
major cardiac events is limited5. 
 
Serum markers define the state of the organism, but fail to identify the 
anatomical site and extent of the problem. Such information could be 
useful when aggressive, invasive treatment strategies are employed. As 
described in the introduction of this thesis, molecular imaging can identify 
extent, localization and timing of biological events leading up to clinical 
syndromes. In this thesis, we have shown feasibility of molecular imaging 
of PS expression to detect biological events leading up to, or contributing 
to, clinical syndromes. 
 
Feasibility of PS expression detection and its correlation to infarct size has 
been shown in patients with acute myocardial infarction6, 7. In such events 
there is abundant PS expression due to large amounts of cell loss in a short 
timeframe. A similar abundance of PS expression is seen in apoptosis of 
endocardial tumors, where large amounts of cells express PS to their 
surface, as shown in chapter six. Finally, the same holds true for PS expres
sion detection in infective endocarditis, as the tissue sections express 
extensive Annexin A5 binding to macrophages8. However, most molecular 
events occur at lower rates. Nevertheless, their continuous character 
bestows them with a profound impact on the organism. 
APOPTOSIS IN HEART FAILURE: A DELICATE BALANCE 
The role of programmed cell death in heart failure has been studied exten
sively by our group and others. Although it was previously believed that 
activation of the cell death program in heart failure patients leads to demise 
of the cardiomyocyte, new insights are developing. Multiple roles have 
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been found for various regulating proteins. For instance, animal models of 
receptor mediated activation or moderate (4fold) overexpression of Gαq 
can induce hypertrophy, whereas high expression levels of Gαq and stress 
due to pregnancy9 or pressure overload10 induces marked left ventricular 
dilatation and a high number of apoptotic myocytes. Administration of a 
polycaspase inhibitor rescues part of the phenotype and improves sur
vival11. GP130 mediated signaling of cytokines can produce hyperthrophy 
due to activation of certain kinases which in turn activate genes that are 
involved in cardiac hypertrophy12. GP130 provides a protective role for 
cardiomyocytes during cytokine release, as conditional knockout of the 
gene and pressure overload induces massive apoptosis and dilatation of 
the left ventricle in mice13. Calcium overload may produce hyperthrophy 
via calcineurin signalling14, but calcium overload, may also trigger cyto
chrome C release and cause demise of the cell due to apoptosis. Thus it 
seems that there is a delicate balance of signals in heart failure causing 
compensatory effects of the myocardium to stress. If stress is increased 
over a certain level, apoptotic signaling sets in. 
 
Interestingly, activation of caspases not necessarily causes demise of cells. 
PCD does contribute to slowly progressive myocardial dysfunction in heart 
failure15. Cytokinemia and ischemic/oxidative stress lead to release of 
cytochrome C from the mitochondria into the cytoplasmic compartment 
and this leads to activation of caspase 316. Active caspase 3 cleaves the 
contractile proteins and activates DNA fragmentation enzymes. The loss of 
cytochrome C signifies the loss of energy production mechanism in mito
chondria. Fragmentation of contractile proteins contributes to decline in 
left ventricular function. As described in the introduction, activation of 
caspase 3 results in expression of PS. However, several protective steps 
inhibit DNA cleavage by inhibition of active caspase 3 fragments. These 
include upregulation of Bcl214 and XIAP like proteins17. Interrupting the 
apoptotic process creates a mechanism of programmed cell survival1820. 
Recently, apoptosisinducing factor (AIF) has shown to function as a mito
chondrial antioxidant in a murine model of heart failure. Mice deficient of 
AIF show increased susceptibility to pressure induced heart failure21. 
Furthermore, addition of antioxidants in mice deficient of AIF prevented 
apoptosis and necrosis and partially rescued the phenotype22. Another 
balance is set, between anti and proapoptotic signalling. 
 
The amount of programmed cell death in heart failure has been studied by 
our group16 and others. Olivetti et al quantified apoptosis in explanted 
cardiomyopathic hearts. They show a prevalence of 0.05% to 0.1% apoptotic 
myocytes in endstage dilated cardiomyopathy patients23. As shown in 
chapter 3, Annexin imaging can detect apoptosis in dilated cardiomyopa
thy. We therefore hypothesize that Annexin A5 imaging of PS expression is 
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a sensitive technique. Such sensitivity is needed when imaging small 
amounts of PS exposure, such as found in atherosclerosis. Chapter 2 shows 
feasibility of detecting unstable plaque in patients with symptomatic 
atherosclerotic carotid artery disease24. 
ANNEXIN A5 IMAGING VERSUS OTHER MOLECULAR IMAGING 
TECHNIQUES 
Molecular imaging strategies have been around for quite some time, as the 
first scintillation camera was designed over 50 years ago by dr Anger at the 
Berkeley laboratory. Since those days a host of molecular targets have 
become available. Due to advances in genetics, bioinformatics and bio
technology, we now understand the biological basis of disease in greater 
detail. Recent advances in molecular imaging technology include monitor
ing of efficacy of stem cell therapy in cardiac repair using either magnetic 
resonance imaging (MRI)25, positron emission tomography (PET)26 or single 
photon emission computed tomography (SPECT) imaging. In addition, 
molecular imaging can be employed detecting effects of gene therapy and 
efficacy of transfection. The latter has been achieved among others by 
activatable imaging agents, where the imageable substrates are changed 
after interacting with their target27, 28. 
 
In atherosclerosis, numerous biological targets have been used for detec
tion of plaque instability. These include imaging of matrix metallopro
teinases (MMPs). MMPs are expressed in macrophages and endothelial 
cells, and are involved in atherosclerotic plaque disruption via enzymatic 
degradation of the fibrous cap. MMP imaging is feasible29, and may identify 
high risk atherosclerotic lesions. Activated macrophages are an attractive 
target for contrast agents. Detectable by PS exposure imaging, activated 
macrophages can also be identified by MRI, as these cells incorporate ultra 
small paramagnetic iron oxide particles (USPIO’s) when activated30. PET 
FDG imaging has been used for detection of increased glucose metabolism 
in unstable atherosclerotic plaques. Prior studies have focused on imaging 
of atherosclerosis in patients undergoing PET FDG imaging for other indica
tions, such as lung carcinoma31, 32. Recent studies were carried out in 
patients with symptomatic carotid artery disease only, combining PET FDG 
and MRI imaging. Davies et al conducted a study in 12 patients with recent 
transient ischaemic attack (TIA), in which they show excellent correlation 
between FDG uptake and localization of TIA. In addition, PET FDG uptake 
colocalizes with atherosclerotic plaques with an unstable morphology on 
high resolution MRI (HRMRI)32. Obviously, carotid angiography detected 
site and severity of the carotid stenoses but was unable to identify the 
unstable plaques reliably. Of note, this is identical to the luminographic 
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limitations of classical coronary angiography. Although the data are uncon
firmed by immunohistochemical analysis of the endarterectomy specimen, 
there is a promising relation between PET uptake, HRMRI imaging and 
clinical symptoms32. Finally, recent publications have shown the use of PET 
FDG imaging in detecting plaque stabilization by statin treatment33, thus 
evaluating biological endpoints for success of treatment. Although PET FDG 
imaging is a very promising concept for carotid artery imaging, high back
ground radiation due to myocardial uptake makes the compound less 
attractive for coronary imaging. HRMRI has the advantage of providing 
better image resolution than PET, CT or SPECT but is susceptible to motion 
artifacts. In addition, the sensitivity of MRI to targeted contrast agents is 
less then 1/1000 when compared to nuclear imaging techniques. Therefore, 
when imaging myocardial and epicardial disease, there is a need for a 
targeted nuclear imaging agent. Annexin A5 may be such an agent. In this 
thesis, we have shown feasibility of detection of unstable carotid plaque24. 
SPECT imaging theoretically has a higher spatial resolution then PET imag
ing. But, when applied clinically, PET is less susceptible to scatter by sur
rounding tissue. Applied clinically, PET provides images with a higher 
resolution due to the use of higher frequencies and radiation energy. In 
addition, quantification of activity of the molecular processes is possible 
only with PET. Future research will require fusion of the abovementioned 
technologies. 
FUTURE DIRECTIONS 
Annexin A5 has been labeled with positron emitting radionuclei, enabling 
PET imaging of PS exposure34,35. To date, no clinical studies have been 
performed. Developing a clinical PET Annexin A5 probe would enable 
detection of PS expression with higher sensitivity and resolution than 
SPECT imaging. In addition, PET is more easily quantifiable, aiding in 
evaluation of success of therapeutic interventions. We would like to sug
gest a clinical approach in which we identify high risk patients on the basis 
of classical risk factors combined with serological markers. Such patients 
could be referred for molecular imaging of high risk lesions. Once local
ized, these lesions could be imaged in detail by intravascular devices such 
as intravascular ultrasound using targeted contast agents, intravascular 
nuclear probes or intravascular OCT. These lesions could then be treated 
by percutaneous coronary interventional strategies and specific molecular 
therapies. Such an approach will need extensive clinical testing to validate 
the diagnostic and prognostic value of molecular imaging strategies, but 
holds the promise of preventive invasive therapy. 
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In heart failure, molecular imaging of programmed cell death can identify 
patients that may benefit from cell death blocking strategies. In addition, 
cell death imaging technology can evaluate the success of cell death block
ing strategies after acute myocardial infarction. The latter approach has 
been tried in animal models. Interestingly, our group has shown an effect 
on infarct size in mammals using the antibiotic minocycline as cell death 
blocking agent (unpublished data). Minocycline has been in use for many 
years as an antibiotic agent and has proven safe. As soon as a clinical 
imaging compound is available, this will be an exciting area to follow. 
Animal models have shown no deleterious side effects on function of 
“rescued” cardiomyocytes, but their clinical function in the course of many 
years will need to be evaluated. 
 
Taken together, this thesis has shown feasibility and possible clinical 
applications of PS expression imaging. The studies performed are not large 
enough to evaluate statistical power, and clinical implementation will 
require further research. However, the results are promising and show 
proof of concept for clinical use of molecular imaging of programmed cell 
death. 
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Despite advances in clinical medicine and medical technology, cardiovas
cular disease remains the leading cause for morbidity and mortality in 
developed countries. A large number of these patients present themselves 
to clinicians only after substantial damage has been caused by cardiovascu
lar disease. Examples of this are patients presenting with myocardial infarc
tion or in a late stage of congestive heart failure. Previously we accepted 
such cases as a natural and unavoidable manifestation of disease. Presently 
it is clear that many of tehse patients suffer from subclinical disease. Most 
of these patients have one or more classical or new risk factors. Classical 
risk factors may identify high risk patients, and additional testing of several 
serum markers may add to further risk stratification. However, such risk 
stratification is unable to predict timing of clinical cardiovascular events. 
 
Cardiovascular events such as congestive heart failure, myocardial and 
cerebral are preceded by specific biological changes. Molecular imaging is 
a novel imaging technology allowing detection of such subclinical biologi
cal changes. Physicians strive to prevent organ damage and functional 
deterioration in patients. Hence, there is an unmet clinical need for tech
nology detecting preclinical molecular changes, and preclinical disease 
states. This thesis focuses on employing radiolabeled Annexin A5 for the 
detection of PS expression in patients suffering from (pre) clinical cardio
vascular disease. We hypothesized that detection of PS expression in 
patients may identify high risk individuals. Such individuals may benefit 
from aggressive treatment. PS expression is a hallmark of apoptosis, but can 
also been found in activated macrophages and activated blood platelets. 
 
This thesis shows feasibility of detection of PS expression in patients 
suffering from dilated cardiomyopathy. PS expression in these patients is 
most likely due to apoptosis. In patients with uptake of radiolabeled An
nexin A5 in the area of the heart the LV function deteriorated, and func
tional class deteriorated. In contrast, patients without noninvasive evi
dence of PS expression remained clinically stable. In this group, left ven
tricular function improved slightly over time. 
 
Furthermore, we have shown the use of Annexin A5 imaging in detection of 
inflammation. Chapter 3 shows the use of radiolabeled Annexin A5 in 
detection of infective endocarditis prior to blood cultures becoming 
positive. Chapter 4 describes the use of Annexin A5 imaging in detection of 
unstable plaque in carotid arteries of patients that have suffered a transient 
ischaemic attack (TIA) or minor stroke. Such patient will benefit from 
surgical therapy. 
 
Finally, this thesis shows the use of molecular imaging with Annexin A5 in 
patients with an unknown intracardiac mass. Intracardiac masses are un
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suitable for biopsy taking due to the high risk of embolic complications. 
Thus, making a diagnosis prior to surgery is often difficult. However, surgi
cal approach may vary significantly when addressing either a benign or 
malignant intracardiac mass. We have shown the use of radiolabeled 
Annexin A5 in making a diagnosis prior to surgical intervention. Chapter 6 
shows the cohort of patients with an unknown intracardiac mass. In the 
cases with a negative scan, no malignant tumors were found. Followup of 5 
years showed an excellent prognosis. Positive scans were associated with 
malignant tumor or infective endocarditis. 
 
These date show that molecular imaging can detect biological changes 
preceding disease. More precisely, this thesis shows feasibility of molecular 
imaging using radiolabeled Annexin A5 for detection of PS expression in 
patients suffering from a wide variety of cardiovascular disease. Annexin 
imaging was able to detect high risk patients developing heart failure, 
infective endocarditis and TIA or stroke. Furthermore, Annexin imaging 
aided in making a diagnosis in patients with tumors unsuitable for biopsy 
taking. Such patients are candidates for aggressive, novel treatment. In risk 
stratifying patients, molecular imaging may improve prognosis in high risk 
patients by enabling prevention of endorgan damage. Additionally, mo
lecular imaging may be used in evaluating success of novel treatment 
strategies as biological effects can be monitored real time, repeatedly. The 
ultimate goal would be to employ insights gained by molecular imaging for 
early, individualized treatment. 
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CHAPTER 8 
Nederlandstalige samenvatting 
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THE ANNEXIN CODE: REVEALING CARDIOVASCULAR DISEASE 
Ondanks de vorderingen in medische kennis en technologie, blijven 
cardiovasculaire ziekten de meest belangrijke oorzaak voor mortaliteit en 
morbiditeit in de westerse wereld. Een groot gedeelte van de patiënten 
komen pas onder de aandacht van de medische wereld nadat een cardio
vasculaire ziekte al uitgebreide schade heeft aangericht. Dit is het geval bij 
patiënten die zich presenteren met een myocardinfarct of in een laat 
stadium van hartfalen. In het verleden werden dergelijke casus geaccep
teerd als een natuurlijke en niet te voorkomen manifestatie van cardiovas
culair lijden. Tegenwoordig is duidelijk dat vele van deze patiënten al 
subklinische ziekte hebben. De meeste van deze mensen hebben één of 
meer klassieke of nieuwe risicofactoren. Risicofactoren kunnen hoog 
risicopatiënten identificeren, en bloedonderzoek kan eventueel nog iets 
bijdragen aan verdere risicostratificatie. Echter, deze manier van risicostra
tificatie kan de timing van cardiovasculaire events zoals een hart of hersen
infarct niet voorspellen. 
 
Cardiovasculaire events zoals hartfalen, hart en herseninfarcten worden 
voorafgegaan door specifieke biologische veranderingen. Moleculaire 
beeldvorming is een nieuwe beeldvormende techniek welke in staat is 
dergelijke subklinische biologische veranderingen waar te nemen. Artsen 
willen weefselschade en achteruitgang in functioneren bij patiënten voor
komen. Daarom is er een vraag naar technologie die zulke biologische 
veranderingen detecteert. Deze promotie focust op het gebruik van gela
beld Annexine A5 voor de detectie van PS expressie in patiënten. PS ex
pressie wordt gezien bij geprogrammeerde celdood en macrofaag en 
plaatjesactivatie. De onderzoekshypothese van dit proefschrift is dat 
detectie van PS expressie helpt bij identificatie van hoogrisico patiënten. 
 
Dit proefschrift toont dat PS expressie detectie mogelijk is bij patiënten 
met een gedilateerde cardiomyopathie (DCM). PS expressie is in dit geval 
een teken van apoptose. Het is in eerdere studies aangetoond dat apoptose 
in een belangrijke mate bijdraagt aan achteruitgang van de functie van het 
hart bij patiënten met een gedilateerde cardiomyopathie. Voor die eerdere 
studies was het echter steeds nodig biopten te nemen van de hartspier. In 
dit proefschrift laten we zien dat door middel van Annexine A5 scans non
invasief PS expressie aangetoond kan worden bij patiënten met DCM. De 
scan lijkt eveneens een voorspellende waarde te hebben: bij patiënten met 
een positieve Annexine A5 scan werd de cardiale functie slechter, en nam 
de algehele conditie af. De cardiale functie en conditie bleef stabiel bij 
mensen met een negatieve scan. 
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Daarnaast werd de Annexine scan gebruikt voor detectie van ontsteking. Bij 
patiënten met de verdenking op een bacteriële ontsteking van het hart, 
endocarditis genaamd, is het belangrijk snel een diagnose te hebben. Als 
behandeling te laat gestart wordt kan een endocarditis veel schade aan de 
hartspier en –kleppen aanrichten, welke vaak maar moeizaam te herstellen 
is. Hoofdstuk 3 laat zien dat Annexine scans endocarditis kunnen detecte
ren voordat bloedkweken positief worden, en zo kan helpen in de vroege 
diagnostiek van endocarditis. 
 
Ontsteking, celdood en plaatjesactivatie worden allemaal gezien bij “slag
aderverkalking”, of atherosclerose. Acute ziekten van hart en bloedvaten 
zoals infarcten worden vaak niet veroorzaakt door langzaam progressieve 
vernauwing van een bloedvat, maar door vorming van een stolsel dat een 
bloedvat afsluit. De plaatsen waar zulk een stolsel ontstaat worden wel 
“kwetsbare plaques” genoemd. In hoofdstuk 4 laten we zien dat Annexine 
scans gebruikt kunnen worden voor aantonen van kwetsbare atherosclero
tische plaques bij patiënten met een TIA (“lichte beroerte”). Het is de hoop 
dat dergelijke scans hersen en hartinfarcten kunnen zien aankomen, zodat 
ze in de toekomst voorkomen kunnen worden. 
 
Tenslotte laat dit proefschrift zien dat Annexine scans gebruikt kunnen 
worden bij patiënten met een massa in het hart. Omdat er geen biopten 
van een intracardiale massa genomen kunnen worden, is vaak onduidelijk 
of het om een goed of kwaadaardig gezwel gaat. Patiënten met een posi
tieve scan hadden ofwel een maligne tumor, ofwel actieve endocarditis of 
een vers trombus. Patiënten met een negatieve scan hadden een goedaar
dig gezwel. 5 Jaar followup liet zien dat patiënten met een negatieve scan 
een uitstekende prognose hadden. 
 
Deze data laten zien dat moleculaire beeldvorming biologische verande
ringen kan detecteren welke voorafgaan aan klinische ziekten. Waarschijn
lijk kunnen hoogrisico patiënten geïdentificeerd worden, gebruik makend 
van met moleculaire beeldvorming. Een dergelijke patiënt kan dan agres
siever behandeld worden met conventionele of nieuwe technieken. Daar
naast kan moleculaire imaging gebruikt worden om het succes van derge
lijke behandeling te evalueren. Het doel is dat met inzichten verkregen 
door moleculaire imaging vroege, geïndividualiseerde behandeling van 
patiënten verwezenlijkt kan worden. 
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Chapter 1, Figure 1: 
 Molecular imaging versus anatomical imaging. Molecular imaging detects changes on a molecu
lar level, preceding the changes in anatomy. Potentially, detecting disease in an early stage may 
aid clinicians and patients, enabling early treatment. In addition, scans can be easily repeated 
studying effect of treatment. Furthermore, information on lesions not suitable for biopsy taking 
can be acquired.  
 
 
 
 
 
Chapter 1, Figure 3: 
 Annexin A5 binds to cells in all stages of the cell death program. Here, Jurkat cells are stimulated 
by Fas ligand. In figure 3A, the early phase of apoptosis is seen. Already we can observe binding 
of fluorescent labeled Annexin A5 to the cell membrane. Figure 3B depicts a later stage, in which 
we see formation of blebs and Annexin A5 binding. Figure 3C is the final stage of apoptosis, the 
cell remnants. These also bind labeled Annexin A5. 
 
3A 3B 3C
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Chapter 1, Figure 4: 
Paw of a chick embryo 
at day 13. Binding of 
labeled Annexin A5 
(note brown staining) 
can de observed in 
interdigit spaces 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: 
Invivo whole heart imaging of mice undergoing ischaemia (I) and reperfusion (R). Images taken 
after 30 minutes of ischaemia and 1 and 8 minutes of reperfusion, respectively. Annexin A5 has 
been labeled with a green fluorescent molecule. Notice the increase in intensity of signal. Via this 
method, the externalization of PS can be monitored in a time dependent manner, allowing real 
time visualization of activation of the cell death program in the beating heart. For full color image 
see page 92. 
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Chapter 1, Figure 6: 
Detection of cell death in a patient with acute myocardial infarction, using technetium labeled 
Annexin A5. The left panel shows perfusion imaging in the acute stage prior to opening of the 
occluded artery. The perfusion defect is used as a measure of the area at risk. The right panel 
shows imaging of the binding of technetium labeled Annexin A5 within the area at risk, indicating 
presence of programmed cell death in the area of infarction. 
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Chapter 3, Figure 1: 
A: Transthoracal echocardiography, parasternal long axis view of the left ventricle. Arrowhead 
depicts mass attached to the mitral valve. Ao = Aorta; LV = Left ventricle. B: Immunohistochemis
try of the intracardiac mass. Brown staining = Annexin A5. Upper panel shows extensive binding 
of Annexin A5 to cell membranes. Lower panel shows colocalisation of a macrophage marker 
(CD68, dark blue staining), and Annexin A5. C: Dual isotope imaging using 201TL and 99mTc 
Annexin A5. Arrowheads point to Annexin A5 uptake in the area of the mitral valve. 
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Chapter 4, Figure 1 : 
Annexin A5 imaging of carotid artery atherosclerosis. Panel A: Annexin imaging in a patient with 
recent TIA. Note enhanced uptake in the left carotid artery region (arrowheads). Panel B: Unstable 
atherosclerotic plaque and Annexin binding to cell membranes, mainly macrophages. Panel C: 
Annexin imaging in remote TIA, no enhanced uptake is observed. Panel D: Stable atherosclerotic 
plaque, absence of Annexin A5 binding to cells.  
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Chapter 5, Figure 1: 
Molecular and anatomical imaging of intracardiac masses. 
Panel IA shows a parasternal long axis view of the left ventricle. There is a clear intracardiac mass 
shown in the area of the mitral valve. Panel IB shows a normal perfusion image of the left 
ventricle (short axis view). Note the absence of uptake of annexin A5 in the same region. Panel IC 
shows histology, no Annexin A5 staining was observerd. 
Panel IIA shows a parasternal long axis view of the left ventricle with a large mass attached to the 
left ventricular wall. Panel IIB shows intense uptake of radiolabeled Annexin A5 in the region of 
the left ventricle. Panel IIC confirms binding of annexin A5 to cells (brown staining). Histology 
showed sarcoma 
Panel IIIA is a cardiac magnetic resonance image. This four chamber view shows a large mass 
attached to the LV apex in the presence of an apical infarct. Panel IIIB shows uptake of radio
labeled Annexin in the area of the LV apex in the left panel. Right panel shows a fusion image 
between low resolution CT and nuclear imaging, confirming the localization of the Annexin 
uptake (LV apex). In this case no cardiac surgery was performed.  
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Het schrijven van een proefschrift is allerminst een solo prestatie. Ook in 
mijn geval was het tot een goed einde brengen van mijn proefschrift alleen 
mogelijk met de hulp van een groot aantal mensen. De teamgeest die ik 
heb mogen ervaren tijdens het doen van dit onderzoek was fantastisch. 
 
Speciale dank gaat uit naar de mensen van het “Annexineteam”. Rond Leo 
Hofstra en Chris Reutelingsperger heeft zich een heel team van Annexine
fans verzameld. Leo, jij als directe begeleider hebt me wegwijs gemaakt in 
de wondere wereld van de wetenschap. Als ik iets van je heb mogen leren 
dan is het je eeuwige optimisme, en de manier waarop je van iedere tegen
slag weer een mogelijkheid tot nieuwe ontdekkingen maakte. Gelukkig 
was er altijd ruimte voor humor. Ik kan me nog de tekeningen herinneren 
bij mijn artikelen. Rookwolkjes en “Bas, verhalen voor bij het haardvuur” 
als ik weer eens te lang van stof was. Bedankt voor een schitterende tijd, 
zowel wetenschappelijk als tijdens extracurriculaire activiteiten. Op de 
squashbaan en tijdens hardlopen was je me de baas, misschien is er nu tijd 
om te trainen en revanche te nemen. Chris, je was een enorm waardevol 
aanspreekpunt bij al mijn biochemische problemen. Dank voor de “hard
core science” ondersteuning aan deze jonge arts.  
 
Promotor prof. dr. H.J.G.M. Crijns, U hebt mij vooral tijdens het laatste deel 
van mijn promotietraject weten aan te zetten tot daadwerkelijk schrijfwerk. 
Het was soms lastig de klinische taken te combineren met het afronden van 
het proefschrift. Mijn gesprekken met u en het inhoudelijk commentaar op 
de stukken hebben de wetenschappelijk interesse weten te behouden 
tijdens mijn jaren in de periferie. Dank! 
 
Professor Narula, dear Jagat. I am grateful for the fruitful discussions we 
had about science. I enjoyed the brief time I had the opportunity to stay at 
you lab in Irvine. The “Indian hospitality” was amazing. I look forward to 
meeting you again in the future. Your enthousiasm for science is conta
gious. It has inspired me and many of my colleagues.  
 
Professor dr. G.A.K. Heidendal, u en uw team hebben mij wegwijs gemaakt 
op de afdeling nucleaire geneeskunde. Ik heb mij altijd een welkome gast 
gevoeld. Dank voor de bereidheid alle nieuwe zaken met u te bespreken.  
Uw relativerende woorden als ons enthousiasme weer eens met ons op de 
loop ging heb ik altijd als positief ervaren. Daarnaast natuurlijk mijn dank 
aan de laboranten van de nucleaire geneeskunde. Het geduld van Marie
Therese Pakbiers, Serve Halders en Denise Janssen kende geen grenzen. 
Altijd waren jullie bereid alle data nog eens voor mij op een rij te zetten, 
me te helpen met uitwerken van scans en de bediening van de apparatuur. 
Ik voel me heel wat veiliger in een hotlab dankzij jullie en jullie collega’s. 
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